Professor Allan David SPIGELMAN
Professor A.D. Spigelman                       2                                     Curriculum
Vitae

                   ...
Professor A.D. Spigelman                         3                                      Curriculum
Vitae

AWARDS
• McNeill...
Professor A.D. Spigelman                        4                                    Curriculum
Vitae

Section of Academic...
Professor A.D. Spigelman                          5                          Curriculum
Vitae

GRANTS
JOURNALS REFEREED
I ...
Professor A.D. Spigelman                   6                                  Curriculum
Vitae

     Thomson JPS. Familial...
Professor A.D. Spigelman                     7                                   Curriculum
Vitae

   3.    Upper gastroin...
Professor A.D. Spigelman                     8                                  Curriculum
Vitae

   23. Pouch adenomas in...
Professor A.D. Spigelman                    9                                  Curriculum
Vitae

   41. Prise en charge de...
Professor A.D. Spigelman                   10                                  Curriculum
Vitae

       Hodgson S, Zauber ...
Professor A.D. Spigelman                     11                                   Curriculum
Vitae

       bowel cancer st...
Professor A.D. Spigelman                   12                                  Curriculum
Vitae

       Wilson P, Spigelma...
Professor A.D. Spigelman                     13                                  Curriculum
Vitae

        2006; 12(10): 3...
Professor A.D. Spigelman                    14                                  Curriculum
Vitae

2.  Under Wraps: an auto...
Professor A.D. Spigelman                    15                                 Curriculum
Vitae

      83: 874-875.
19.   ...
Professor A.D. Spigelman                   16                                 Curriculum
Vitae

     duodenal disease in f...
Professor A.D. Spigelman                     17                                  Curriculum
Vitae

10. Bile reflux and gas...
Professor A.D. Spigelman                     18                                   Curriculum
Vitae

28. Carcinogens in bil...
Professor A.D. Spigelman                    19                                  Curriculum
Vitae

47. Randomized controlle...
Professor A.D. Spigelman                      20                                   Curriculum
Vitae

    measures of outco...
Professor A.D. Spigelman                      21                                   Curriculum
Vitae

    MH, Forbes A, Spi...
Professor A.D. Spigelman                   22                                  Curriculum
Vitae

   (2): Abstracts, 6.
104...
Professor A.D. Spigelman                    23                                 Curriculum
Vitae

   syndromes: evaluation....
Professor A.D. Spigelman                     24                                  Curriculum
Vitae

9. DNA adducts in the f...
Professor A.D. Spigelman                      25                                   Curriculum
Vitae

    Australasian Soci...
Professor A.D. Spigelman                     26                                   Curriculum
Vitae

45. Experience with a ...
Professor A.D. Spigelman                    27                                  Curriculum
Vitae

13. Peroperative enteros...
Professor A.D. Spigelman                      28                                   Curriculum
Vitae

    Castle Polyposis ...
Professor A.D. Spigelman                       29                                     Curriculum
Vitae

42. A Survey of Su...
Professor A.D. Spigelman                    30                                  Curriculum
Vitae

    DR, Spigelman AD. UK...
Download.doc
Download.doc
Download.doc
Download.doc
Download.doc
Download.doc
Download.doc
Download.doc
Upcoming SlideShare
Loading in...5
×

Download.doc

1,587

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,587
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Download.doc"

  1. 1. Professor Allan David SPIGELMAN
  2. 2. Professor A.D. Spigelman 2 Curriculum Vitae PART 2: CAREER HISTORY 2006 - : Professor of Surgery, University of NSW, St.Vincent’s Hospital Clinical School Director of Cancer Services, St.Vincent’s & Mater Health Service, Sydney Honorary Senior Medical Officer, Hunter New England Area Health Service Member, Governing Council, International Society for Gastrointestinal Hereditary Tumours (2005 - ) Conjoint Professor of Surgical Science, Faculty of Health, University of Newcastle (2004 - ) Member, N.S.W Medical Board (representing Universities of N.S.W; 2003 - ) Founder and Chair, Hunter Family Cancer Service (1997 - ) Chair, Advisory Committee, NSW & ACT Hereditary Cancer Registers (1997 - 2006 ) 1997-2005: Director, Hunter New England Clinical Governance Unit (2005 -2006) Area Director of Cancer Services, Hunter New England Area Health Service (2005) Area Director of Cancer Services, Hunter Area Health Service (2003 - 4) Director of Clinical Governance, Hunter Area Health Service (1999-2004) Chair, Division of Surgery, John Hunter Hospital (1998 - 1999) Director, John Hunter Hospital Surgical Audit Unit (1997 – 2001) Professor of Surgical Science, Faculty of Health, University of Newcastle (1997 – 2003) 1990-1997: Senior Lecturer and Honorary Consultant Surgeon, Academic Surgical Unit, St. Mary's Hospital, London and the Central Middlesex Hospital, London Director, St. Mary’s Hospital Breast Group Director of the St. Mary's Hospital Day Care Unit Lead Clinician, St. Mary's Hospital Carelink Information Systems Project Lead Clinician, St. Mary's Hospital Family Cancer Service Director, St. Mary's Hospital Breast Group Assistant Director, Medical Education Unit, St. Mary's Hospital Medical School Honorary Senior Research Fellow, The Polyposis Registry, St. Mark's Hospital Member, Academic Board of the St. Mark's Academic Institute 1988-1989: Surgical Research Fellow, St. Mark's Hospital & Professorial Surgical Unit, St. Bartholomew's Hospital Honorary Clinical Assistant, St. Mark's Hospital 1985-1987: Senior Surgical Registrar, Kings College Rotation, London Surgical Registrar University College Hospital, London Senior Surgical Registrar, University College Hospital and the Middlesex Hospital, London Honorary Clinical Assistant - St. Mark's Hospital, London 1985: Private Practice, Sydney; Visiting Surgeon, 4 RAAF Hospital Air Base Butterworth, Malaysia 1981-1984: Surgical Registrar, Advanced Training Scheme, Royal Australasian College of Surgeons - Prince of Wales Hospital, Sydney 1977-1980: Resident Medical Officer, Royal Prince Alfred Hospital, Sydney Junior Registrar, Surgery, Prince of Wales Hospital, Sydney Senior Resident Medical Officer, Surgery, Prince of Wales Hospital, Sydney
  3. 3. Professor A.D. Spigelman 3 Curriculum Vitae AWARDS • McNeill Love Prize for Excellence in Surgery, The Royal Northern Hospital, London 1987 • Alan Edwards Memorial Prize, The Royal Society of Medicine, for Best Presentation to the Clinical Section 1988-1989 • Hewlett Packard Innovation and Quality in Health Care ‘Golden Helix’ Award, United Kingdom, awarded for establishing the St. Mary’s Hospital, London, One-Stop Breast Service 1995 • Australian Cancer Network, Australian Cancer Society & the Clinical Oncological Society of Australia – Certificate of Exemplary Service; for commitment to Development of Best Practice Guidelines 2000 • NSW Department of Health Baxter Better Health Care Awards (2000) Excellence in Health Care Category, “The Prevention of Infection in Prosthetic Joint Replacement” • Certificate of Appreciation for significant contribution to the development of the Princess Alexandra Hospital Health Service District, Brisbane, Patient Safety System, 2002 • Commonwealth Bank Quality Award, "Quit Smoking for Surgery" project 2003 ($500) • Best free paper presented by a Fellow at the Royal Australasian College of Surgeons Annual Scientific Congress, Brisbane, May 5-9 2003 ($500): Title: 'What happens to patients after discharge?’ • Peter Reizenstein Prize for best paper published in the International Journal for Quality in Health Care in 2002 (£500) for: Adverse Events in Surgical Patients in Australia • Hunter Medical Research Institute / New South Wales Cancer Council Prize (2003) for Outstanding Achievements in Cancer Research ($2,000) • Baxter NSW Health Award (2003) Information Management Category, “Aiming for a Safer Patient Environment” • Featured Researcher – Colorectal Society of Australasia 2005 MEMBERSHIP OF LEARNED SOCIETIES & PROFESSIONAL ORGANISATIONS The Royal Australasian College of Surgeons The Royal College of Surgeons of England The Surgical Research Society of Great Britain and Ireland (1989 to 2001); name change to Society of Academic and Research Surgery (2001); resigned in 2004 The Royal Society of Medicine - Member of Council, Clinical Section; 1991-1994; Vice-President, Clinical Section; 1994; Library Representative 1995-1997) The British Society of Gastroenterology (to 2002) The British Medical Association (1988 - 2002) The St. Mark's Association The Leeds Castle Polyposis Group (1988 – 2004); Member of Council 1999 - 2003; Chairman, LCPG Upper Gastrointestinal Disease Committee International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (to 2004) The International Society for Gastrointestinal Hereditary Tumours (InSIGHT - created by merger of the above 2 Groups; 2004 - ; elected Member of Governing Council 2005 - ) International Society of University Colon and Rectal Surgeons (to 2005) The Association of Coloproctology of Great Britain and Ireland (to 2003) The European Cancer Prevention Organisation (1990 – 1997) British Association of Day Surgery (1994 - 1998) North West Thames General Surgeons Club (1995 - 1997) British Medical Informatics Society (1994 - 1998) Medical and Dental Education Network (United Kingdom 1993 - 1997) Surgical Research Society of Australia (Life Membership) Colorectal Surgical Society of Ausralasia (to 2005) Australian Resource Centre for Hospital Innovations (Member, Local Management Committee 1998-2000) Hunter Postgraduate Medical Institute (Board Member, 2001 - 2006) Australian Gastro-Intestinal Trials Group (2001 - )
  4. 4. Professor A.D. Spigelman 4 Curriculum Vitae Section of Academic Surgery, Royal Australasian College of Surgeons (2002 - ) The Cancer Council NSW (2006 - ) RESEARCH DEGREE SUPERVISION (The University of Newcastle) • Elective Surgery Resulting in Adverse Events in Australian Hospitals. Co-supervisor of PhD candidate, Ms. Ashley Kable (1998-2004) – awarded 2004 • New South Wales Colorectal Cancer Patterns of Care Survey. Co-supervisor of PhD candidate, Dr. David Leong (1998 - 2002) • Prognostic factors in Abdominal Aortic Aneurysm Surgery. Supervisor of BMedSci candidate, Mr. Stuart McKenzie (1999) - awarded • Surgeons’ Practices and Attitudes Regarding Euthanasia. Co-supervisor of MS candidate, Dr. Charles Douglas, funded by a competitive grant from the Royal Australasian College of Surgeons Foundation Scholarship in Surgical Ethics (1999) • Colorectal and Prostate Cancer Research. Supervisor of PhD candidate Dr Daniel McGrath (2001-2004) • Aviation and Surgery: Behaviour in the Operating Room. Co-supervisor of PhD candidate Ms Rebecca Atkins (2002-2005)
  5. 5. Professor A.D. Spigelman 5 Curriculum Vitae GRANTS JOURNALS REFEREED I am a referee for the following journals: 1. The British Journal of Surgery 2. The European Journal of Cancer Prevention 3. Surgical Oncology 4. International Journal of Colorectal Disease 5. European Journal of Gastroenterology and Hepatology 6. Cancer Detection and Prevention 7. Quality in Health Care 8. American Journal of Gastroenterology 9. The Medical Journal of Australia 10. British Medical Journal 11. Gut 12. Australian & New Zealand Journal of Surgery 13. Journal of the American College of Physicians 14. Colorectal Disease 15. Journal of Quality in Clinical Practice 16. Clinical Evidence 17. Thrombosis Research 18. Scandinavian Journal of Gastroenterology 19. International Journal for Quality in Health Care 20. Digestive and Liver Disease EDITORIAL BOARDS 1. Therapeutics and Clinical Risk Management 2. Hereditary Cancer in Clinical Practice – published under the auspices of the UICC PUBLICATIONS: BOOKS 1. Familial Adenomatous Polyposis and Other Polyposis Syndromes. (eds) Phillips RKS, Spigelman AD, Thomson JPS. ISBN 0-340-56755-4. London: Edward Arnold 1994. 2. The National Colorectal Cancer Care Survey - Australian Clinical Practice in 2000. Spigelman AD, McGrath DR. ISBN 1 876992 00 X www.ncci.org.au Commissioned by the National Cancer Control Initiative on behalf of the Commonwealth Department of Health and Aged Care, 2002. 3. The NSW Colorectal Cancer Care Survey 2000. Part 1. Surgical Management. Armstrong K, O’Connell D, Leong D, Spigelman A, Armstrong B. ISBN 1 86507 073 4 www.cancercouncil.com.au The Cancer Council NSW April 2004. 4. The New South Wales Colorectal Cancer Care Survey Part 2 - Chemotherapy Management. Armstrong K, O'Connell DL, Leong D, Yu XQ, Spigelman AD, Armstrong BK. ISBN 1 86507 078 8. www.cancercouncil.com.au The Cancer Council NSW July 2005. CHAPTERS 1. Management of Familial Adenomatous Polyposis. Spigelman AD Hodgson SV, Thomson JPS in (ed) Henry MM. Bailliere's Clinical Gastroenterology: Anorectal Disorders. London: Bailliere Tindall 1992; 6 (1): 75-94. 32 2. P-Postlabelling studies of target tissues and bile from patients with familial adenomatous polyposis and from unaffected controls. Scates DK, Spigelman AD, Phillips RKS, Venitt S in (eds) Phillips DH, Castegnaro M, Bartsch H. Postlabelling Methods for Detection of DNA Adducts. Lyon, International Agency for Research on Cancer 1993; 357-364. 3. Nomenclature: Familial Adenomatous Polyposis (Bussey-Gardner Polyposis). Spigelman AD, Thomson JPS, Phillips RKS in (eds) Phillips RKS, Spigelman AD,
  6. 6. Professor A.D. Spigelman 6 Curriculum Vitae Thomson JPS. Familial Adenomatous Polyposis and Other Polyposis Syndromes. London: Edward Arnold 1994; xiii-xiv. 4. The Upper Gastrointestinal Tract. Spigelman AD, Phillips RKS in (eds) Phillips RKS, Spigelman AD, Thomson JPS. Familial Adenomatous Polyposis and Other Polyposis Syndromes. London: Edward Arnold 1994;106-127. 5. Peutz Jeghers Syndrome. Spigelman AD, Phillips RKS in (eds) Phillips RKS, Spigelman AD, Thomson JPS. Familial Adenomatous Polyposis and Other Polyposis Syndromes. London: Edward Arnold 1994; 188-202. 6. Introduction, History and Registries. Spigelman AD, Thomson JPS in (eds) Phillips RKS, Spigelman AD Thomson JPS. Familial Adenomatous Polyposis and Other Polyposis Syndromes. London: Edward Arnold 1994; 3-14. 7. Genetics. Hodgson SV, Spigelman AD in (eds) Phillips RKS, Spigelman AD, Thomson JPS. Familial Adenomatous Polyposis and Other Polyposis Syndromes. London: Edward Arnold 1994; 26-35. 8. Open Repair of Groin Hernias. Spigelman AD in (eds) Darzi A, Monson JRT. Laparoscopic Inguinal Hernia Repair. Oxford: Isis Medical Media Ltd. 1994; 6-17. 9. Cholecystectomy and Colon Cancer. Spigelman AD, in (eds) Darzi A, Grace PA, Pitt HA. Bouchier-Hayes D. Techniques in the Management of Gallstone Disease. London: Blackwell Science 1995; 218-223. 10. Open hernia repair. Spigelman AD. MATTU Handbook. RCSE 1995. 14. Epidemiology and Pathogenesis of Large Bowel Cancer. Spigelman AD in (ed) Allen- Mersh T. Surgical Oncology (Companion to Bailey and Love's Short Practice of Surgery). London: Chapman and Hall 1996; 205-216. 15. The Small Bowel, Colon, Rectum and Anus. Spigelman AD, Phillips RKS in (eds) Fielding JWL, Allum WH. Premalignancy and Early Cancer in General Surgery. Oxford: Oxford University Press 1996; 37-65. 13. Screening and Surveillance in Familial Adenomatous Polyposis. Spigelman AD, Williams CB in (eds) Beger HG, Warshaw AL, Buchler M, Carr-Locke D, Neoptolemos JP, Russell C, Sarr M. The Pancreas. Blackwell Scientific Publications 1997; 1311-1315. 14. Inherited Bowel Cancer. Spigelman AD, in (ed) Phillips RKS. A Companion to Specialist Surgical Practice: Colorectal Surgery, Volume IV, Colorectal and Small Bowel Surgery. London: W.B. Saunders 1998; 33-42. 15. Inherited Bowel Cancer. Spigelman AD, in (ed) Phillips RKS. A Companion to Surgical Practice: Colorectal Surgery, 2nd edition: Harcourt Brace & Company Ltd 2001; 35-52. 16. Acute Abdominal Conditions – Surgical Aspects. Spencer J & Spigelman AD, in (eds) Henry MM, Thompson JN. Clinical Surgery. London: W.B. Saunders 2001; 315-326. 17. Clinical Governance – An approach to delivering safer care. Spigelman A, in (eds) Emslie S, Williams S, Barraclough B. Enhancing the Safety of Care, Australian Safety & Quality Council www.safetyandquality.org & Northern Territory Department of Health and Community Services, ISBN 0 7245 3372 9, 2002. 18. Acute Abdominal Conditions. Spigelman AD, in (eds) Henry MM, Thompson JN. Clinical Surgery. London, 2nd Edition: W.B. Saunders 2005; 365-376. PAPERS (Peer reviewed) 1. Isolated Congenital Pulmonary Incompetence: Case Report and Literature Review. Spigelman AD, Wright JS. ANZ J Surg 1984; 54; 177-181. 2. Cholecystectomy, duodeno-gastric reflux and polyposis. Spigelman AD, Thomson JPS, Phillips RKS. J Roy Soc Med 1989; 82: 436-7.
  7. 7. Professor A.D. Spigelman 7 Curriculum Vitae 3. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Spigelman AD, Williams CB, Talbot IC, Domizio P, Phillips RKS. Lancet 1989; ii: 783-785. 4. Cancer and the Peutz-Jeghers syndrome. Spigelman AD, Murday V, Phillips RKS. Gut 1989; 30: 1588-1590. 5. Management of the Peutz-Jeghers patient. Spigelman AD, Phillips RKS. J Roy Soc Med 1989; 82: 681. 6. Pneumatosis Coli: a cause of diagnostic confusion. Spigelman AD, Williams CB, Ansell JK, Rutter KRP, Phillips RKS. Br J Surg 1990; 77: 155. 7. Towards decreasing the relaparotomy rate in the Peutz Jeghers syndrome: the role of peroperative small bowel endoscopy. Spigelman AD, Thomson JPS, Phillips RKS. Br J Surg 1990; 77: 301-302. 8. Vitamin C levels in patients with familial adenomatous polyposis. Spigelman AD, Uff CR, Phillips RKS. Br J Surg 1990; 77: 508-509. 9. Mutagenicity of bile and duodenal adenomas in familial adenomatous polyposis. Spigelman AD, Crofton-Sleigh C, Venitt S, Phillips RKS. Br J Surg 1990; 77: 878-881. 10. Upper gastrointestinal tract pathology in familial adenomatous polyposis: results from a prospective study of 102 patients. Domizio P, Talbot IC, Spigelman AD, Phillips RKS, Williams CB. J Clin Path 1990; 43: 738-743. 11. Screening for cancer and precancer of the oesophagus, stomach and duodenum. Spigelman AD, Phillips RKS. Hospital Update 1991; 17(3): 220-227. 12. Biliary bile acid profiles in familial adenomatous polyposis. Spigelman AD, Owen RW, Hill MJ, Phillips RKS. Br J Surg 1991; 78: 321-325. 13. Duodeno-gastric reflux and gastric adenomas: a scintigraphic study in patients with familial adenomatous polyposis. Spigelman AD, Granowska M, Phillips RKS. J Roy Soc Med 1991; 84: 476-478. 14. Tumours of the liver, bile ducts, pancreas and duodenum in a single patient with familial adenomatous polyposis. Spigelman AD, Farmer KCR, James M, Richman PI, Phillips RKS. Br J Surg 1991; 78: 979-980. 15. DNA adducts, detected by 32P-postlabelling, in the foregut of patients with familial adenomatous polyposis and in unaffected controls. Spigelman AD, Scates DK, Venitt S, Phillips RKS. Carcinogenesis 1991; 12: 1727-1732. 16. An initial experience of day surgery repair of inguinal hernias. Spigelman AD. J One-Day Surg 1991; 1 (2): 22-23. Plus erratum in J One-Day Surg 1991; 1 (3): 24. 17. Colorectal cancer: new evidence for the adenoma/carcinoma sequence. Spigelman AD, Venitt S. Carter R. Lancet 1992; 340: 210-211. 18. Rectal polyposis as a guide to duodenal polyposis in patients with familial adenomatous polyposis. Spigelman AD, Williams CB, Phillips RKS. J Roy Soc Med 1992; 85: 77-79. 19. DNA adducts, detected by 32P-postlabelling, in the intestine of rats given bile from patients with familial adenomatous polyposis and from unaffected controls. Scates DK, Spigelman AD, Phillips RKS, Venitt S. Carcinogenesis 1992; 13: 731-735. 20. Inguinal hernia repair. Spigelman AD. Update 1993; 47: 436-445. 21. Iatrogenic pancreatitis in familial adenomatous polyposis (FAP). Nugent KP, Spigelman AD, Williams CB, Phillips RKS. Gut 1993; 34: 1269-1270. 22. Surgical polypectomy of duodenal adenomas in familial adenomatous polyposis: experience of two European centres. Penna C, Phillips RKS, Tiret E, Spigelman AD. Br J Surg 1993; 80: 1027-1029.
  8. 8. Professor A.D. Spigelman 8 Curriculum Vitae 23. Pouch adenomas in patients with familial adenomatous polyposis. Nugent KP, Spigelman AD, Nicholls RJ, Talbot IC, Neale K, Phillips RKS. Br J Surg 1993; 80: 1620. 24. Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Nugent KP, Spigelman AD, Phillips RKS. Dis Colon & Rectum 1993; 36: 1059-1062. 25. DNA adducts, detected by 32P-postlabelling, in DNA treated in vitro with bile from patients with familial adenomatous polyposis and from unaffected controls. Scates DK, Spigelman AD, Nugent KP, Phillips RKS, Venitt S. Carcinogenesis 1993; 14: 1107-1110. 26. Randomised controlled clinical trial of the effect of Sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Nugent KP, Farmer KCR, Spigelman AD, Williams CB, Phillips RKS. Br J Surg 1993; 80: 1618-1619. 27. Gallbladder dysplasia in patients with familial adenomatous polyposis Nugent KP, Spigelman AD, Talbot IC, Phillips RKS. Br J Surg 1994; 81: 291-292. 28. Familial adenomatous polyposis: recent genetic advances. Spigelman AD. Br J Surg 1994; 81: 321-322. 29. Images in Clinical Medicine: Situs inversus. Spigelman AD. N Eng J Med 1994; 330: 606. 30. Evidence for adenoma-carcinoma sequence in the duodenum of patients with familial adenomatous polyposis (FAP). Spigelman AD, Talbot IC, Penna C, Nugent KP, Phillips RKS, Costello C, DeCosse JJ & The Leeds Castle Polyposis Group (Upper Gastrointestinal Committee). J Clin Path 1994; 47: 709-710. 31. Glutathione S-transferase mu phenotype in patients with familial adenomatous polyposis and in unaffected controls. Spigelman AD, Nugent KP, Penna C, Phillips RKS. Cancer Det and Prev 1994; 18 (4): 253-258. 32. Surveillance of duodenal polyps in familial adenomatous polyposis: progress report. Nugent KP, Spigelman AD, Williams CB, Talbot IC, Phillips RKS. J Roy Soc Med 1994; 87: 704-706. 33. For debate: Endoscopic surveillance for colorectal neoplasia. Spigelman AD. Br J Surg 1994; 81: 1664-5. 34. Bile acids do not form adducts when incubated with DNA in vitro. Scates DK, Spigelman AD, Venitt S. Carcinogenesis 1994; 15: 2945-2948. 35. Caffeine phenotyping of Cytochrome P4501A2, N-acetyltransferase, and xanthine oxidase in patients with familial adenomatous polyposis. Spigelman AD, Farmer KCR, Oliver S, Nugent KP, Bennett PN, Notarianni LJ, Dobrocky P, Phillips RKS. Gut 1995; 36: 251-254. 36. High pH reduces in-vitro DNA adduct formation by bile from patients with familial adenomatous polyposis: might antacids reduce duodenal polyposis? Scates DK, Venitt S, Phillips RKS, Spigelman AD. Gut 1995; 36: 918-921. 37. Appearance of artefacts when using 32P-postlabelling to investigate DNA adduct formation by bile acids in vitro: lack of evidence for covalent binding. Scates DK, Spigelman AD, Venitt S. Carcinogenesis 1995; 16: 1489-1491. 38. Familial adenomatous polyposis and the upper gastrointestinal tract. Spigelman AD. Seminars in Colon & Rectal Surgery 1995; 6: 26-28. 39. Gall-bladder agenesis and associated congenital anomalies. Yiangou C, Shorey B, Spigelman AD. HPB Surgery 1995; 8: 253-255. 40. Undergraduate surgery - coping with change. Spigelman AD. Med Ed 1995; 5: 7.
  9. 9. Professor A.D. Spigelman 9 Curriculum Vitae 41. Prise en charge des patients a risque de cancer colorectal hereditaire. (Management of patients at risk of hereditary colorectal cancer). Spigelman AD. Acta Endoscopica 1995; 25: 63-70. 42. Upper intestinal surveillance in Familial Adenomatous Polyposis. Debinski HS, Spigelman AD, Hatfield A, Williams CB, Phillips RKS. Eur J Cancer 1995; 31A: 1149-1163. 43. Photodynamic therapy for polyps in familial adenomatous polyposis - a pilot study. Mlkvy P, Messman H, Debinski H, Regula J, Conio M, MacRobert A, Spigelman A, Phillips R, Bown SG. Eur J Cancer 1995; 31A: 1160-1165. 44. Polyposis: The Peutz-Jeghers Syndrome. Spigelman AD, Arese P, Phillips RKS. Br J Surg 1995; 82: 1311-1314. 45. DNA ploidy on cytological and tissue sections of breast lumps: a comparison using image analysis. Sarker SK, Mendiola R, Spigelman AD, Walker M, Coleman DV. Anal Quant Cytol Histol 1996; 18: 19-22. 46. p53 expression in duodenal tumours in patients with familial adenomatous polyposis. Kashiwagi H, Spigelman AD, Talbot IC, Phillips RKS. Br J Surg 1996; 83: 225-228. 47. Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Nugent KP, Spigelman AD, Phillips RKS. Dis Colon & Rectum 1996; 39: 659-662. 48. Risk of extracolonic cancer in familial adenomatous polyposis. Nugent KP, Spigelman AD, Phillips RKS. Br J Surg 1996; 83: 1121-1122. 49. Differences in the levels and pattern of DNA-adduct labelling in human cell lines MCL-5 and CCRF, proficient or deficient in carcinogen-metabolism, treated in vitro with bile from familial adenomatous polyposis patients and from unaffected controls. Scates DK, Spigelman AD, Phillips RKS, Venitt S. Carcinogenesis 1996; 17: 707-713. 50. Colorectal polyp counts and cancer risk in familial adenomatous polyposis. Debinsky HS, Neale K, Love S, Spigelman AD, Phillips RKS. Gastroenterology 1996; 110: 1028-1030. 51. Can we safely delay or avoid prophylactic colectomy in familial adenomatous polyposis? Phillips RKS, Spigelman AD. Br J Surg 1996; 83: 769-770. 52. A modifying locus for familial adenomatous polyposis may be present on chromosome 1p35-p36. Tomlinson IPM, Neale K, Talbot IC, Spigelman AD, Williams CB, Phillips RKS, Bodmer WF. J Med Genet 1996; 33: 268-273. 53. The use of 32P-postlabelling in studies of the nature and origin of DNA adducts formed by bile from patients with familial adenomatous polyposis and from normal patients. Scates DK, Spigelman AD, Phillips RKS, Venitt S. Mutation Research 1997; 387:113-125. 54. Screening modalities in Familial Adenomatous Polyposis and Hereditary Non- Polyposis Colorectal Cancer. Spigelman AD. Gastrointestinal Endoscopy Clinics of North America 1997; 7: 81-86. 55. p53 and k-ras status in duodenal adenomas in Familial Adenomatous Polyposis. Kashiwagi H, Spigelman AD, Talbot IC, Debinski HS, McKie AB, Lemoine NR, Phillips RKS. Br J Surg 1997; 84: 826-829. 56. Nuclear DNA content of fine needle aspirates of invasive ductal carcinomas of the breast. Sarker S, Spigelman A, Walker M, Coleman D. Analytical Cellular Pathology 1997; 13: 1-8. 57. Peutz-Jeghers’ Disease: most, but not all, families are compatible with linkage to 19p13.3. Olschwang S, Markie D, Seal S, Neale K, Phillips R, Cottrell S, Ellis I,
  10. 10. Professor A.D. Spigelman 10 Curriculum Vitae Hodgson S, Zauber P, Spigelman A et al. Journal of Medical Genetics 1998; 35(1): 42-44. 58. Malignant change in a duodenal adenoma in familial adenomatous polyposis: report of a case. Nakatsubo N, Kashiwagi H, Okumura M, Kamoshida T, Takahashi A, Spigelman AD. American Journal of Gastroenterology 1998; 93:1566-1568. 59. Duodenal Polyposis in Familial Adenomatous Polyposis. Spigelman AD. Scand J Gastro 1999; 34: 545. 60. Large bowel cancer: guidelines and beyond. Thomas R, Spigelman A, Armstrong B. Med J Aust 1999; 171: 284-285. 61. Does more equal less or does less equal more? Spigelman AD. J Qual Clin Practice 2000; 20: 55. 62. A survey of surgical audit in Australia: whither clinical governance? Eno LM, Spigelman AD. J Qual Clin Practice 2000; 20: 2-4. 63. An audit of open and laparoscopic inguinal hernia repair. Eno LM, Spigelman AD. J Qual Clin Practice 2000; 20: 56-59. 64. Gastroduodenal Lesions in Familial Adenomatous Polyposis. Kashiwagi H, Spigelman AD. Surg Today 2000; 30: 675-682. 65. Hereditary Non Polyposis Colorectal Cancer in 95 families: Differences and Similarities between Mutation-Positive and Mutation-Negative Kindreds. Scott RJ, McPhillips M, Meldrum CJ, Fitzgerald PE, Adams K, Spigelman AD, du Saret D, Tucker K, Kirk J & the Hunter Family Cancer Service. Am J Hum Genet 2001; 68: 118-127. 66. Relationship between APC Genotype, Polyp Distribution and Oral Sulindac Treatment in the Colon and Rectum of Patients with Familial Adenomatous Polyposis. Guldenschuh I, Hurlimann R, Muller A, Ammann R, Mullhaupt B, Dobbie Z, Gian-Franco Z, Flury R, Seelentag W, Roth J, Myenberger C, Fried M, Hoppeler T, Spigelman AD, Scott RJ. Dis Colon & Rectum 2001; 44: 1090-99. 67. Familial Adenomatous Polyposis: more evidence for disease diversity and genetic heterogeneity. Scott RJ, Meldrum C, Crooks R, Spigelman AD, Kirk J, Tucker K, Koorey D, the Hunter Cancer Family Service. Gut 2001; 48: 508-514. 68. The intention to hasten death: a survey of attitudes and practices of surgeons in Australia. Douglas CD, Kerridge IH, Rainbird KJ, McPhee JR, Hancock L, Spigelman AD. Med J Aust 2001; 175: 511-515. 69. Randomized Placebo-controlled Trial of Gastric Acid-Lowering Therapy on Duodenal Polyposis and Relative Adduct Labeling in Familial Adenomatous Polyposis. Wallace MH, Forbes A, Beveridge IG, Spigelman AD, Hewer A, Venitt S, Phillips RKS. Dis Colon & Rectum 2001; 44: 1585-1589. 70. Preventive Measures in Peutz-Jeghers syndrome. McGrath DR, Spigelman AD. Family Cancer 2001; 1 (2): 121-5. 71. Prevention of orthopaedic wound infections – a quality improvement project. Swan J, Douglas P, Asimus M, Spigelman AD. J Qual Clin Practice 2001; 21: 149-153. 72. Duodenal cancer in patients with Familial Adenomatous Polyposis – results of a 10 year prospective study. Groves CG, Saunders BP, Spigelman AD, Phillips RKS. Gut 2002; 50: 636-641. 73. Gastrointestinal Surgery. Spigelman AD, McGrath DR, Levy RD. Med J Aust 2002; 175: 15. 74. Inhibition of proliferation of a colon cancer cell line by Indole-3-Carbinol. Frydoonfar H, McGrath DR, Spigelman AD. Colorectal Disease 2002; 4: 205-207. 75. Clinical Perspectives: Hereditary Colorectal Cancer: keeping it in the family – the
  11. 11. Professor A.D. Spigelman 11 Curriculum Vitae bowel cancer story. McGrath DR, Spigelman AD. Internal Medicine 2002; 32: 325-330. 76. A novel strategy to stop cigarette smoking in surgical patients. Haile MJ, Wiggers JH, Spigelman AD, Knight J, Considine RJ, Moore K. ANZ J Surg 2002; 72; 618-622. 77. Hereditary Colorectal Cancer: Selected Internet Viewings. McGrath DR, Spigelman AD. Ann R Coll Surg Engl 2002; 84: 218. 78. Adverse events in surgical patients in Australia. Kable A, Gibberd R, Spigelman AD. Int J Quality in Health Care 2002; 14: 269-276. 79. Impact of microsatellite testing and mismatch repair protein expression on the clinical interpretation of genetic testing in hereditary nonpolyposis colorectal cancer. Ward R, Meldrum C, Williams R, Molkany E, Scott R, Turner J, Hawkins N, Spigelman A. J Cancer Res and Clin Oncology 2002; 128: 403-411. 80. Mutation analysis of the STK11/LKB1 gene and clinical characteristics of an Australian series of Peutz-Jeghers syndrome patients. Scott RJ, Crooks R, Meldrum CJ, Thomas L, Smith CJA, Mowat D, McPhillips M, Spigelman AD. Clinical Genetics 2002; 62: 282-287. 81. Familial Adenomatous Polyposis and Duodenal Lymphoma: report of a case. Frizelle FA, Hemmings CT, Whitehead MR, Spigelman AD. Dis Colon & Rectum 2003; 12: 1698-1701. 82. The variable effect on proliferation of a colon cancer cell line by the citrus fruit flavanoid Naringenin. FrydoonFar H, McGrath DR, Spigelman AD. Colorectal Disease 2003; 5: 149-152. 83. The effect of Indole-3-Carbinol and sulforaphane on a prostate cancer cell line. FrydoonFar H, McGrath DR, Spigelman AD. ANZ J Surg 2003; 73; 154-156. 84. Overview of the National Colorectal Cancer Care Survey - Australian Clinical Practice in 2000. McGrath DR, Spigelman AD. Colorectal Disease 2003; 5: 588-589. 85. Audit of surgeon awareness of readmissions with venous thrombo-embolism. Swan J, Spigelman AD. Internal Medicine 2003; 33: 578-580. 86. Titanic waiting lists - what lies beneath? Spigelman AD. ANZ J Surg 2003; 73: 781. 87. Why are are we waiting? Spigelman AD. ANZ J Surg 2003; 73: 873. 88. Measuring clinical audit and peer review practice in a diverse health care setting. Spigelman AD, Swan JR. ANZ J Surg 2003; 73: 1041-1043. 89. Sulforaphane inhibits growth of a colon cancer cell line. FrydoonFar H, McGrath DR, Spigelman AD. Colorectal Disease 2004; 6: 28-31. 90. Hereditary non-polyposis colorectal cancer and the role of hPMS2 and hEXO1 mutations. Thompson E, Meldrum CJ, Crooks R, McPhillips M, Thomas L, Spigelman AD, Scott RJ. Clinical Genetics 2004; 65: 215-225. 91. Management of colorectal cancer patients in Australia: the National Colorectal Cancer Survey. McGrath DR, Leong DC, Armstrong BK, Spigelman AD. ANZ J Surg 2004; 74: 55-64. 92. Extracolonic Polyposis in Familial Adenomatous Polyposis (FAP): So Near and Yet So Far. Spigelman AD. Gut 2004; 53: 322. 93. Complications after discharge for surgical patients. Kable A, Gibberd R, Spigelman AD. ANZ J Surg 2004; 74: 92-97. 94. Is there a link between work related stress and colorectal cancer? Spigelman AD, Dwyer P. Med J Aust 2004; 180: 339-340. 95. Relative frequency and morphology of cancers in STK11 mutation carriers. Lim W, Olschwang S, Keller JJ, Westerman AM, Menko FH, Boardman LA, Scott RJ, Trimbath J, Giardiello FM, Gruber SB, Gille JJP, Offerhaus GJA, de Rooij FWM,
  12. 12. Professor A.D. Spigelman 12 Curriculum Vitae Wilson P, Spigelman AD, Phillips RKS, Houlston RS. Gastroenterology 2004; 126: 1788-1794. 96. People with colorectal cancer – can we help them do better? Spigelman AD. ANZ J Surg 2004; 74: 401-402. 97. Germline missense changes in the APC gene and their relationship to disease. Scott RJ, Crooks R, Rose L, Attia J, Thakkinstian A, Thomas L, Spigelman AD, Meldrum CJ. Hereditary Cancer in Clinical Practice 2004; 2: 81-91. 98. In the beginning there was colectomy: current surgical options in Familial Adenomatous Polyposis. McGrath DR, Spigelman AD. Hereditary Cancer in Clinical Practice 2004; 2 (4): 153-160. 99. Elective open abdominal aortic aneurysm repair: a seven year experience. Mackenzie S, Swan J, D’Este C, Spigelman AD. Therapeutics and Clinical Risk Management 2005; 1: 27-31. 100.The NSW & ACT Hereditary Cancer Registers. Weir L, Spigelman AD, Scott RJ, Kirk J, Zeckendorf S, Sitas F. Aust Fam Physician 2005; 34: 53-58. 101.A programme for reducing smoking in preoperative surgical patients: a randomized controlled trial. Wolfenden L, Wiggers J, Knight J, Campbell E, Rissel C, Kerridge R, Spigelman AD, Moore K. Anaesthesia 2005; 60(2): 172-9. 102.Skin antiseptics and the risk of operating theatre fires. Swan J, Spigelman AD. ANZ J Surg 2005; 75: 556 - 558. 103.A review of the Australian Incident Monitoring System. Spigelman AD, Swan J. ANZ J Surg 2005; 75: 657 - 661. 104.Mutation analysis of the MYH gene in an Australian series of colorectal polyposis patients with or without germline APC mutations. Kairupan CF, Meldrum CJ, Crooks R, Milward EA, Spigelman AD, Burgess B, Groombridge C, Kirk J, Tucker K, Ward R, Williams R, Scott RJ. International Journal of Cancer; 2005: 116: 73-77. 105.Increasing smoking cessation care in a preoperative clinic: a randomized ontrolled trial. Wolfenden L, Wiggers J, Knight J, Campbell E, Spigelman AD, Kerridge R, Moore K. Preventive Medicine 2005; 41: 284-290. 106.Surgeon and hospital volume and the management of colorectal cancer patients in Australia. McGrath DR, Leong DC, Gibberd R, Armstrong B, Spigelman AD. ANZ J Surg 2005; 41: 901-910. 107.MLH1 germline epimutations as a factor in hereditary non-polyposis colorectal cancer. Hitchins M, Williams R, Cheong K, Halani N, Ap Lin V, Packham D, Ku S, Buckle A, Hawkins N, Burn J, Gallinger S, Goldblatt J, Kirk J, Tomlinson I, Scott R, Spigelman A, Suter C, Martin D, Suthers G, Ward R. Gastroenterology 2005; 129 (5): 1392-1399. 108.An interloper revealed: DNA analysis and the identification of an Egyptian Mummy. Sowada K, Matheson C, Spigelman A, Spigelman M. Bulletin of the Australian Centre for Egyptology 2005; 16: 101-116. 109.Surgical accountability: a framework for trust and change. Thompson A, Stonebridge PA, Spigelman AD. MJA 2005; 183: 500. 110.Governance and Innovation: Experience with a policy on the introduction of new interventional procedures. Spigelman AD. ANZ J Surg 2006; 76: 9-13. 111.Frequency and spectrum of cancers in the Peutz-Jeghers Syndrome. Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJP, Keller JJ, Westerman AM, Scott RJ, Lim W, Trimbath JD, Giardiello FM, Gruber SB, Offerhaus GJA, de Rooij FWM, Wilson JHP, Hansmann A, Moslein G, Royer- Pokora B, Vogel T, Phillips RKS, Spigelman AD, Houlston RS. Clin Cancer Res
  13. 13. Professor A.D. Spigelman 13 Curriculum Vitae 2006; 12(10): 3209-3215. 112.STK11 status and intussusception risk in Peutz-Jeghers syndrome. Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJP, Keller JJ, Westerman AM, Scott RJ, Lim W, Trimbath JD, Giardiello FM, Gruber SB, Offerhaus GJA, de Rooij FWM, Wilson JHP, Hansmann A, Moslein G, Royer- Pokora B, Vogel T, Phillips RKS, Spigelman AD, Houlston RS. Submitted. OTHER PUBLICATIONS 1. Breast Disease. Spigelman AD. Regional Therapeutic News July 1995, No 8. 2. Training of overseas doctors in the United Kingdom. Spigelman A. Surgery (Scalpel) 1995; 13 (5): 2-3. 3. Hereditary Bowel Cancer: Prevention is Better Than Cure. Spigelman AD. Cancer Council Professional Update August 1998. 4. Surgical Adverse Events Study. Kable AK, Gibberd RW, Spigelman AD. Report to the NSW Ministerial Advisory Committee for Quality in Health Care. 1999. 5. Clinical Practice Guidelines. Familial Aspects of Cancer: A guide to clinical practice. NHMRC, Canberra 1999 (member of Working Party). 6. What a difference a day can make. Same Day Surgical and Endoscopic Procedures Policy. NSW Health, 1999 (member of Reference Group). 7. New Initiatives in Patient Safety. Spigelman A. J Med and Health Sci Newsletter 2000; 103: 2-3. 8. New Initiatives for Conjoint Staff. Spigelman A. J Med and Health Sci Newsletter 2001; 107: 13. 9. International Forum presents common challenges in hereditary bowel cancers. Spigelman A. Newsletter: NSW & ACT Hereditary Bowel Cancer Registers August 2001. 10. Anticancer Compounds in Cruciferous Vegetables. Spigelman A, McGrath D. J Med and Health Sci Newsletter 2002; 110: 13. 11. Hunter Area Health Service: Clinical Risk Management Framework & Patient Safety Process. Douglas P, Spigelman AD. February 2003 (1st ed.); August 2003 (2nd ed.). 12. The National Colorectal Cancer Care Survey - Australian Clinical Practice in 2000. Spigelman AD, McGrath DR. RACS Surgical News January / February 2003; 4(1): 15. 13. The National Colorectal Cancer Care Survey - Australian Clinical Practice in 2000. McGrath DR, Spigelman AD. Medical Oncology Group of Australia Newsletter March 2003, p. 7. 14. Managing Clinical Risk and Improving Patient Safety. Douglas P, Spigelman A. J Med and Health Sci Newsletter 2003; 116: 11. 15. Patient Care must be the top priority. Allan Spigelman. Newcastle Herald, December 26, 2003, page 9. 16. Hospital Waiting Lists. Interview with Norman Swan, The Health Report, ABC National Radio, December 18, 2003. Transcript available at www.abc.net.au/rn/talks/8.30/helthrpt/stories/s1010746.htm 17. Making the Health System Safer: New Interventional procedures. Spigelman A. J Med and Health Sci Newsletter 2004; 120: 10. VIDEOS 1. Interviewing techniques for interviewers. Royal Australasian College of Surgeons. 1998
  14. 14. Professor A.D. Spigelman 14 Curriculum Vitae 2. Under Wraps: an autopsy of three Egyptian Mummies. Astarte Resources. 1998 3. Science Frontiers 3 – Ancient Autopsies. Beyond Productions. 2000 4. Essentials of Physical Examination of the Abdomen. University of Newcastle Audio- Visual Centre. 2002 BOOK REVIEWS 1. Management of Colorectal Cancer. (Eds.) H. Bleiberg, P. Rougier and H-J Wilke. Martin Dunitz (1998). Cancer Forum 1998; 22 (3): 20. 2. Textbook of Surgery. (Eds.) GJA Clunie, J Tjandra, DMA Francis. Blackwell Scientific Asia (1999). Med J Aust 1999; 170: 137. 3. 20 Common Problems. Surgical Problems and Procedures in Primary Care. (Eds) Lynge DC, Weiss BG. New York: McGraw-Hill 2001. Med J Aust 2001; 175: 489. 4. Minimally Invasive Cancer Management. (Eds.) F L Greene, Heniford BT. Springer (2001). Cancer Forum 2001; 25 (3): 176. 5. Inherited Cancer Syndromes – Current Clinical Management. C Neal Ellis (Ed.) 2004, Springer Germany. ANZ J Surg 2004; 74: 1035. LETTERS 1. The functional result of pelvic ileal reservoir in 10 patients with familial adenomatous polyposis. Spigelman AD, Phillips RKS. Ann R Coll Surg Eng 1989; 71: 269. 2. Genes and carcinogens. Spigelman AD, Phillips RKS, Venitt S. Lancet 1989; ii: 1210. 3. Association of congenital hypertrophy of the retinal pigment epithelium with familial adenomatous polyposis. Spigelman AD, Phillips RKS. Br J Surg 1990; 77: 1195. 4. Biliary bile acid profiles in familial adenomatous polyposis authors reply. Spigelman AD, Owen RW, Hill MJ, Phillips RKS. Br J Surg 1992; 79: 90. 5. Bile and the growth of intestinal polyps. Spigelman AD, Venitt S, Phillips RKS. Arch Surg 1992; 127: 361. 6. Ileo-anal pouch procedure. Spigelman AD, Phillips RKS. ANZ J Surg 1992; 62: 495. 7. Duodenal cancer in polyposis patients. Spigelman AD, Jensen W, Bulow S. Gastroenterology 1992; 103: 1995. 8. Follow-up in familial adenomatous polyposis. Nugent KP, Spigelman AD, Williams CB, Talbot IC, Phillips RKS. Lancet 1993; 341: 1225. 9. Screening and management of FAP. Spigelman AD, Nugent KP, Phillips RKS. Gut 1993; 34: 1292. 10. Surveillance of ampullary adenomas in familial adenomatous polyposis. Kashiwagi, H, Spigelman AD, Debinski HS, Talbot IC, Phillips RKS. Lancet 1994; 344: 1582. 11. Colomastology as a subspeciality of surgical oncology. Spigelman AD. Br J Surg 1995: 82: 280. 12. Genetic susceptibility to colorectal cancer in patients under 45 years of age. Spigelman AD. Br J Surg 1995; 82: 423. 13. Effect of sulindac on small polyps in familial adenomatous polyposis. Debinski HS, Trojan J, Nugent KP, Spigelman AD, Phillips RKS. Lancet 1995; 355: 855-6. 14. Relationship between colorectal and prostate cancer. Spigelman AD. Dis Colon & Rectum 1995; 38: 555. 15. Faxed electronic summaries are valued by general practitioners. BMJ 1995; 311: 746-747. 16. Caffeine phenotyping in patients with familial adenomatous polyposis may shed light on sporadic colon cancer and acetylator status - reply. Spigelman AD, Phillips RKS. Gut 1996; 38: 153. 17. A missed breast cancer. Spigelman AD. ANZ J Surg 1996; 66: 118. 18. Polyposis: the Peutz Jeghers Syndrome. Spigelman AD. Phillips RKS. Br J Surg 1996;
  15. 15. Professor A.D. Spigelman 15 Curriculum Vitae 83: 874-875. 19. Coding message. Spigelman A. Hospital Doctor January 16, 1997; 24. 20. Organisation of Breast Care and Teaching. Spigelman A. J R Soc Med 1997; 90(9): 25-26. 21. Surveillance of the duodenum in patients with familial adenomatous polyposis. Spigelman A, Phillips RKS. Gut 1998; 42:144-145. 22. Maybe general surgery no longer exists as a specialty. Spigelman A. BMJ 1998; 316: 778. 23. Assessment of a scoring system for breast imaging. Spigelman AD Br J Surg 1998; 85: 1722. 24. Early discharge after surgery for breast cancer. Hotel wards are good option for patients. Spigelman AD BMJ 1999; 318:1217. 25. Magnetic Resonance Spectroscopy and Breast Cancer: Comment. Spigelman AD. ANZ J Surg 1999; 69: 531. 26. Think regional. Spigelman AD. Sydney Morning Herald August 23, 1999. 27. Current surgical practice in screening for colorectal cancer based on family history criteria. Spigelman AD. Br J Surg 1999; 86: 426-427. 28. Alcohol abstinence: patient or surgeon? Spigelman AD. www.bmj.com. eBMJ Rapid Responses. May 25, 1999. bmj.com/cgi/eletters/318/7194/1311#3296. 29. Consultant surgeons’ opinions of the skills required of basic surgical trainees. Spigelman AD. Br J Surg 2000; 87: 517. 30. Familial adenomatous polyposis: extending the role of dye spray at colonoscopy. Spigelman A. Dis Colon Rectum 2000; 43 (5): 726. 31. Tumour site, sex, and survival in colorectal cancer. Scott RJ, Spigelman AD. Lancet 2000; 356: 857. 32. Colorectal cancer gene testing utility underestimated. Spigelman AD. www.bmj.com. eBMJ Rapid Responses. May 29, 2001. bmj.com/cgi/eletters/322/7293/1052#14819. 33. Assisted dying study. Spigelman AD. www.bmj.com. eBMJ Rapid Responses. November 29, 2001. bmj.com/cgi/eletters/323/7324/1268#17844. 34. Indole-3-Carbinol: a novel anti-parasitic treatment? McGrath DR, Frydoonfar H, Spigelman AD. www.bmj.com eBMJ Rapid Responses. January 21, 2003. (http://bmj.com/cgi/eletters/325/7374/1221#28840). 35. Safety and Efficacy of New Interventional Procedures. Spigelman AD. www.bmj.com eBMJ Rapid Responses. February 14, 2003. bmj.com/cgi/eletters/326/7385/347#29634. 36. Is biliary pain a colic? McGrath DR, Spigelman AD. www.bmj.com eBMJ Rapid Responses. February 24, 2003 http://bmj.com/cgi/eletters/325/7365/639#29909. 37. Pathogenesis and clinical management of hereditary non-polyposis colorectal cancer. Spigelman AD. Br J Surg 2003; 90: 370. 38. What would the patient choose? McGrath DR, Spigelman AD. www.bmj.com eBMJ Rapid Responses. April 23, 2003 http://bmj.com/cgi/eletters/326/7394/832. 39. Re: re: complications after discharge for surgical patients. Kable A, Gibberd R, Spigelman A. ANZ J Surg 2004; 74: 805. 40. Genetic testing: a round table conversation. Spigelman A, Burgess B, Groombridge C, Scott RJ. International Med Journal 2004; 34: 587-8. 41. Colorectal cancer site varies with age and gender. McGrath DR, Spigelman AD. Postgraduate Medical Journal on line, December 8, 2004 http://pmj.bmjjournals.com/cgi/eletters/80/949/667. 42. Spigelman A, Gani J. Re: Pylorus-preserving pancreaticoduodenectomy for advanced
  16. 16. Professor A.D. Spigelman 16 Curriculum Vitae duodenal disease in familial adenomatous polyposis (p.1157-1164). Br J Surg 2005; 92: 253. & Br J Surg 2004; online. 43. Detoxification enzymes in the duodenal mucosa of patients with familial adenomatous polyposis (p.754-755). Spigelman AD. 14 July 2005, online at http://www.bjs.co.uk/bjsCda/cda/microViewCorrespondence.do;jsessionid=90F4F981B ED74D74887B258CD189AF3C? DOI=10.1002%2Fbjs.4996&issueDOI=10.1002%2Fbjs.v92%3A6&vid=2. 44. Re: Submission 8259, Response to 'Factors affecting morbidity, mortality and survival in patients undergoing surgery for rectal cancer in a district general hospital' by Macadam R et al. Spigelman AD. e-letter Ann R Coll Surg Eng April 2006; http://www.rcseng.ac.uk/publications/eletters/. 45. Germline mutations of APC are not associated with inherited colorectal polyposis. Hitchins M, Suter C, Wong J, Cheong K, Hawkins N, Leggett B, Scott R, Spigelman A, Tomlinson I, Martin D, Ward R. Gut 2006; 55: 586-7. REVIEWS 1. General Surgery. Spigelman AD. Medical Review 1994; 1 (1): 16. 2. General Surgery. Spigelman AD. Medical Review 1995; 1 (2): 20. 3. General Surgery. Spigelman AD. Medical Review 1995; 1 (3): 20. 4. General Surgery. Goldberg A, Spigelman AD. Medical Review 1995; 1 (4): 19-20. 5. General Surgery. Spigelman AD. Medical Review 1996; 2 (2): 16. 6. General Surgery. Spigelman AD. Medical Review 1996; 2 (3): 18. 7. General Surgery. Spigelman AD. Medical Review 1996; 2 (4): 19. SERIES EDITED 1. Short Stay Surgery. Hospital Update 1993. ABSTRACTS 1. Foregut screening in familial adenomatous polyposis (FAP). Spigelman AD, Phillips RKS, Williams CB, Bussey HJR. Gut 1988; 29: A1445. 2. Gastro-duodenal adenomas in polyposis – is bile the missing link? SpigelmanAD, Williams CB, Granowska M, Phillips RKS. Gut 1989; 30: A710-11. 3. Ornithine decarboxylase activity in the upper gastro-intestinal tract in familial adenomatous polyposis. Alstead EM, Brito FCG, Spigelman AD, Phillips RKS, Clark ML, Farthing MJG. Clinical Science 1989; 77 (21): 25. 4. Peroperative enteroscopy in Peutz-Jeghers polyposis. Phillips RKS, Spigelman AD, Thomson JPS. Gut 1989; 30: A1464. 5. Desmoid tumours and viruses. Spigelman AD, Argent S, Wells C, Crofton-Sleigh C, Venitt S, Phillip RKS. Int J Colorect Dis 1990; 5: 53. 6. Gastro-duodenal adenomas in polyposis – is bile the missing link? Spigelman AD, Williams CB, Crofton-Sleigh C, Venitt S, Granowska M, Phillips RKS. Int J Colorect Dis 1990; 5: 54. 7. Selected Summaries: Look at the duodenum in familial polyposis. Spigelman AD, Talbot IC, Williams CB, et al. Reviewed by Likier HM, Kurtz C. Gastroenterology 1990; 98: 1092-1093. 8. Evaluation of ornithine decarboxylase (ODC) activity as a marker for premalignancy in the stomach and duodenum. Alstead EM, Brito FCG, Spigelman AD, Phillips RKS, Clark ML, Farthing MJG. Gastroenterology 1990; 98: A269. 9. DNA adducts in the foregut of patients with familial adenomatous polyposis. Spigelman AD, Phillips RKS, Scates DK, Venitt S. In: Abstracts of the World Congresses of Gastroenterology. Sydney 1990. Abingdon: The Medicine Group (UK) Ltd 1990: FP 592.
  17. 17. Professor A.D. Spigelman 17 Curriculum Vitae 10. Bile reflux and gastric adenomas in patients with familial adenomatous polyposis. Spigelman AD, Granowska M, Phillips RKS. In: Abstracts of the World Congresses of Gastroenterology. Sydney 1990. Abingdon: The Medicine Group (UK) Ltd 1990: FP 595. 11. Rectal polyposis severity – a guide to duodenal polyposis severity in familial adenomatous polyposis? Spigelman AD, Williams CB, Phillips RKS. In: Abstracts of the World Congresses of Gastroenterology. Sydney 1990. Abingdon: The Medicine Group (UK) Ltd 1990: PP 203. 12. Bile reflux and gastric adenomas in patients with familial adenomatous polyposis (FAP). Spigelman AD, Granowska M, Phillips RKS. Gut 1990; 31: A1202-3. 13. Excess of DNA-adducts in the foregut of patients with familial adenomatous polyposis. Spigelman AD, Scates DK, Venitt S, Williams CB, Phillips RKS. Gut 1990; 31: A1200. 14. Detection by 32P-Postlabelling of DNA adducts in the upper gastrointestinal tract of patients with familal adenomatous polyposis. Spigelman AD, Phillips RKS, Scates DK, Venitt S. Br J Cancer 1990; 62: 541. 15. Relationship between rectal and duodenal polyposis in familial adenomatous polyposis. Spigelman AD, Williams CB, Phillips RKS. Br J Surg 1990; 77: 1421. 16. Significant excess of DNA-adducts in the foregut of patients with familial adenomatous polyposis. Spigelman AD, Scates DK, Venitt S, Phillips RKS. Br J Surg 1991; 78: 758. 17. Bile and DNA damage in an animal model. Spigelman AD, Scates DK, Venitt S, Phillips RKS. Gut 1991; 32: A1240. 18. Acetylator status: link between hepatic metabolism and colorectal cancer. Farmer KCR, Oliver SE, Spigelman AD, Bennett PN, Phillips RKS. Gut 1991; 32: A1255. 19. Gastric and duodenal polyps in familial adenomatous polyposis. Talbot IC, Domizio P, Spigelman AD, Williams CB, Phillips RKS. Int J Colorect Dis 1991; 6: 232-3. 20. Bile and familial adenomatous polyposis: an update. Spigelman AD, Williams CB, Venitt S, Crofton-Sleigh C, Scates DK, Owen RW, Hill MJ, Granowska M, Talbot IC, Farmer CK, Phillips RKS. Int J Colorect Dis 1991; 6: 233. 21. Evidence at the DNA-base level for the presence of carcinogens in the foregut of patients with familial adenomatous polyposis (FAP). Venitt S, Spigelman AD, Scates DK, Phillips RKS. Int J Colorect Dis 1991; 6: 233. 22. Prospective placebo controlled double blind trial of sulindac in the management of upper gastrointestinal polyps in familial adenomatous polyposis (FAP). Farmer KCR, Spigelman AD, Williams CB, Phillips RKS. Int J Colorect Dis 1991; 6: 233-4. 23. Assessment of pharmacogenetic polymorphisms in familial adenomatous polyposis. Farmer KCR, Spigelman AD, Phillips RKS, Lledo P, Abrams SML. Int J Colorect Dis 1991; 6: 235. 24. Significant excess of DNA-adducts in the foregut of patients with familial adenomatous polyposis (FAP). Spigelman AD, Scates DK, Venitt S, Phillips RKS. Eur J Surg Res 1991; 23 (Suppl 1): 6. 25. DNA adducts in the gut of rats given bile from patients with familial adenomatous polyposis and controls. Scates DK, Venitt S, Spigelman AD, Phillips RKS. Mutagenesis 1991; 6(5): 438. 26. Acetylation status in familial polyposis and colorectal carcinoma. Oliver SE, Farmer KC, Spigelman AD, Phillips RKS, Bennett PN, Notarianni LJ. Br J Clin Pharm 1991; 32(5): 650P. 27. Duodenal polyp progression: a longitudinal study in patients with familial adenomatous polyposis (FAP). Nugent KP, Spigelman AD, Williams CB, Phillips RKS. Gut 1992; 33 (Supplement No 1): S73.
  18. 18. Professor A.D. Spigelman 18 Curriculum Vitae 28. Carcinogens in bile: results of a bioassay. Spigelman AD, Scates DK, Venitt S, Phillips RKS. Br J Surg 1992; 79: 452. 29. 32P-Postlabelling studies on the in vitro genotoxicity of bile from patients with familial adenomatous polyposis and controls. Scates DK, Spigelman AD, Phillips RKS, Radley S, Neoptolemos JP, Venitt S. Mutagenesis 1992; 7: 365. 30. Acetylator status: a link between hepatic metabolism and colorectal cancer. Farmer KCR, Oliver SE, Spigelman AD, Bennett PN, Phillips RKS. Dis Colon Rectum 1992; 35(5): P41-2. 31. Abnormal P4501A2 activity in patients with familial adenomatous polyposis. Spigelman AD, Oliver SE, Farmer KCR, Notarianni LJ, Bennett PN, Phillips RKS. Br J Surg 1992; 79: 1230. 32. Randomised controlled clinical trial of Sulindac on intestinal polyposis in patients with FAP. Nugent KP, Farmer KCR, Spigelman AD, Williams CB, Phillips RKS. Gut 1992; 33 (Supplement No 2): S33. 33. A prospective randomized double-blind placebo-controlled trial of sulindac in the management of gastrointestinal polyps in familial adenomatous polyposis (FAP). Farmer KCR, Nugent KP, Spigelman AD, Williams CB, Phillips RKS. Journal of Gastroenterology and Hepatology 1992; 7: A32. 34. Pouches in patients with familial adenomatous polyposis are not at increased risk for neoplasia. Nugent KP, Spigelman AD, Nicholls RJ, Talbot IC, Phillips RKS. Br J Surg 1993; 80: 661. 35. Analysis of deaths in familial adenomatous polyposis treated by colectomy and ileorectal anastomosis. Nugent KP, Spigelman AD, Phillips RKS. Br J Surg 1993; 80: 662. 36. Sulindac and intestinal polyps: a randomised controlled trial. Spigelman AD, Nugent KP, Farmer KCR, Williams CB, Phillips RKS. Cancer Det Prev 1993; 17(1): 191. 37. Carcinogen metabolism and DNA adducts in patients at high risk for intestinal cancer and in controls. Spigelman AD, Venitt S, Scates DK, Nugent KP, Penna C, Foulds S, Bennett PN, Phillips RKS. Cancer Det Prev 1993; 17(1): 231. 38. Bile and DNA adducts – an in-vitro genotoxicity study. Spigelman AD, Scates DK, Venitt S, Nugent KP, Phillips RKS. Gut 1993; 34: S7. 39. Outcome of duodenotomy for duodenal polyposis in patients with familial adenomatous polyposis. Spigelman AD, Penna C, Nugent KP, Phillips RKS. Gut 1993; 34: S20. 40. P4501A2 activity in patients with colorectal cancer and familial polyposis (FAP) and their at risk relatives. Notarianni LJ, Oliver S, Bennett PN, Farmer KC, Spigelman AD, Phillips RKS. Br J Clin Pharm 1994; 35: . 41. Pouches in patients with familial adenomatous polyposis (FAP) are not at increased risk for neoplasia. Nugent KP, Spigelman AD, Nicholls RJ, Talbot IC, Neale K, Phillips RKS. Int J Colorect Dis 1994; 9: 52. 42. Duodenal polyp follow up in FAP. Spigelman AD, Nugent KP, Williams CB, Phillips RKS. Int J Colorect Dis 1994; 9: 53. 43. The role of duodenotomy in the treatment of duodenal polyposis. Spigelman AD, Penna C, Nugent KP, Tiret E, Phillips RKS. Int J Colorect Dis 1994; 9: 53. 44. Further evidence that FAP bile contains an excess of DNA damaging agents. Venitt S, Spigelman AD, Scates DK, Nugent KP, Phillips RKS. Int J Colorect Dis 1994; 9: 54. 45. Assessment of hepatic metabolism of carcinogens in FAP and control patients. Spigelman AD, Nugent KP, Bennett PN, Penna C, Foulds S, Phillips RKS. Int J Colorect Dis 1994; 9: 54. 46. Coexisting adenomas and periampullary cancer in FAP patients. Talbot IC, Penna C, Nugent KP, Phillips RKS, Spigelman AD. Int J Colorect Dis 1994; 9: 54.
  19. 19. Professor A.D. Spigelman 19 Curriculum Vitae 47. Randomized controlled trial of Sulindac on intestinal polyposis in FAP. Nugent KP, Farmer KCR, Spigelman AD, Williams CB, Phillips RKS. Int J Colorect Dis 1994; 9: 56. 48. p53 overexpression is closely correlated with grade of duodenal neoplasms in familial adenomatous polyposis (FAP). Kashiwagi H, Spigelman AD, Talbot IC, Phillips RKS. Gut 1994; 35 (Supplement No 5): S39. 49. Germline APC mutation at codon 1061 is associated with severe duodenal polyposis but not high colonic polyp counts in familial adenomatous polyposis (FAP). Debinski HS, Pack K, Cottrell S, Hodgson SV, Spigelman A, Phillips RKS. Gut 1994; 35 (Supplement No 5): S40. 50. GST Mu1 genetic polymorphism in familial adenomatous polyposis (FAP). Debinski HS, Cottrell S, Phillips RKS, Spigelman AD. Gut 1994; 35 (Supplement No 5): S63. 51. The relation between germline APC mutations at codon 1309 and severity of duodenal polyposis in familial adenomatous polyposis (FAP). Debinski HS, Cotterell S, Hodgson SV, Spigelman A, Phillips RKS. Journal of Gastroenterology and Hepatology 1994; 9 (5): A103. 52. GST Mu1 genetic polymorphism in familial adenomatous polyposis (FAP). Debinski HS, Cottrell S, Phillips RKS, Spigelman AD. Journal of Gastroenterology and Hepatology 1994; 9 (5): A99. 53. Progression of duodenal polyps in familial adenomatous polyposis (FAP). Debinski HS, Nugent KP, Williams CB, Talbot IC, Phillips RKS, Spigelman AD. Journal of Gastroenterology and Hepatology 1994; 9 (5): A109. 54. Might antacids reduce duodenal polyposis in patients with familial adenomatous polyposis? Scates DK, Venitt S, Phillips RKS, Spigelman AD. Br J Surg 1995; 82: 701. 55. Liposome mediated delivery of the adenomatous polyposis coli gene into a colonic cancer cell line. Hargest R, Williamson R (Spigelman AD). Br J Surg 1995; 82: 691. 56. DNA ploidy studies of sporadic colorectal polyps. Tahir-Kheli ND, Sarker SK, Levine TS, Spigelman AD, Coleman DV. J Path 1995; 175: Suppl. 119A. 57. p53 alteration occurs more frequently than ras mutation in duodenal adenomas in familial adenomatous polyposis. Kashiwagi H, Spigelman AD, Desai D, Debinski HS, Talbot IC, Phillips RKS. J Path 1995; 175: Suppl. 120A. 58. Colorectal polyp density equates with cancer risk in Familial Adenomatous Polyposis. Debinski HS, Neale K, Love S, Phillips RKS, Spigelman AD. Dis Colon & Rectum 1995; 38: P40. 59. Photodynamic therapy for the endoscopic treatment of polyps in familial adenomatous polyposis. Mlkvy P, Messman H, Ng TM, Pauer M, Regula J, Conio M, Debinski H, Spigelman A, Phillips R, Bown SG. Gut 1995; 36 (Suppl 1): A39. 60. Colorectal polyp density equates with cancer risk in familial adenomatous polyposis. Debinski HS, Neale K, Spigelman A, Phillips RKS. Gastroenterology 1995; 108: A458. 61. Endoscopic ultrasound (EUS) – a new tool for assessment of the foregut in FAP patients. Debinski HS, Muller A, Spigelman AD, Hatfield A, Phillips RKS. Gastroenterology 1995; 108: A459. 62. Genotype-phenotype correlation in familial adenomatous polyposis (FAP). Debinski HS, Pack K, Hodgson S, Cottrell S, Neale K, Spigelman AD, Phillips RKS. Gastroenterology 1995; 108: A459. 63. GST Mu1 genetic polymorphism in familial adenomatous polyposis (FAP). Debinski HS, Cottrell S, Phillips RKS, Spigelman AD. Gastroenterology 1995; 108: A459. 64. A prospective double-blind placebo controlled study of the management of duodenal and rectal polyps in familial adenomatous polyposis with low dose aspirin, using several
  20. 20. Professor A.D. Spigelman 20 Curriculum Vitae measures of outcome. Debinski HS, Desai D, Spigelman AD, Phillips RKS. Gastroenterology 1995; 108: A459. 65. Sulindac has maximal effect on small but not large polyps in the duodenum in patients with familial adenomatous polyposis. Debinski HS, Trojan J, Love S, Nugent KP, Spigelman AD, Phillips RKS. Gastroenterology 1995; 108:A460. 66. Is the liver implicated in chronic ulcerative colitis associated colon cancer? Debinski HS, Rogers L, Nugent K, Spigelman AD, Phillips RKS. Gastroenterology 1995; 108: A807. 67. Regression of small duodenal polyps after sulindac treatment in patients with FAP. Trojan J, Debinsky HS, Spigelman AD, Williams CB, Phillips RKS. Gut 1995; 37(2): A136. 68. Photodynamic therapy for polyps in familial polyposis – first report. Messman H, Mlkvy P, Debinski H, Regula J, Conio M, MacRobert A, Spigelman A, Phillips R, MacRobert A, Bown S. Endoscopy 1995; 27(7): 69. Photodynamic therapy for polyps in familial polyposis – first report. Mlkvy P, Messman H, Debinski H, Regula J, Conio M, MacRobert A, Spigelman A, Phillips R, Bown S. Int J Colorectal Dis 1996; 11: 103. 70. Might antacids reduce duodenal polyposis in patients with familial adenomatous polyposis? Scates DK, Venitt S, Phillips RKS, Spigelman AD. Int J Colorectal Dis 1996; 11: 104. 71. Colorectal polyp density equates with cancer risk in familial adenomatous polyposis (FAP). Debinski HS, Neale K, Love S, Spigelman AD, Phillips RKS. Int J Colorectal Dis 1996; 11: 105-106. 72. Genotype-phenotype correlation in FAP. Debinski HS, Pack K, Love S, Neale K, Cotterell S, Hodgson SV, Williams CB, Spigelman AD, Phillips RKS. Int J Colorectal Dis 1996; 11: 106. 73. Prostaglandins – their role in carcinogenesis. Nugent KP, Spigelman AD, Phillips RKS. Int J Colorectal Dis 1996; 11: 109. 74. GST Mu1 genetic polymorphism in familial adenomatous polyposis (FAP). Debinski HS, Cottrell S, Phillips RKS, Spigelman AD. Int J Colorectal Dis 1996; 11: 107-108. 75. p53 overexpression is a hallmark of duodenal adenomas in familial adenomatous polyposis. Kashiwagi H, Spigelman AD, Debinski HS, Neale K, Talbot IC, Phillips RKS. Int J Colorectal Dis 1996; 11: 108. 76. Bile from transgenic mice carrying a mutation in the Apc gene induces more DNA damage than does bile from wild-type mice from the same genetic background. Scates DK, Venitt S, Spigelman AD, Phillips RKS, Mathers JC, Fodde R. Gut 1996; 38 (suppl 1): A18. 77. Familial adenomatous polyposis: the risk of extracolonic cancer. Nugent KP, Spigelman AD, Phillips RKS. Int J Colorectal Disease 1996; 11: 132. 78. Studies of the nature and origin of DNA adducts formed by bile from patients with familial adenomatous polyposis and from normal patients. Venitt S, Scates DK, Spigelman AD, Phillips RKS Int J Colorectal Disease 1997; 12: 344-366. 79. Bile from transgenic mice carrying a mutation in the Apc gene induces more DNA damage than does bile from wild-type mice from the same genetic background. Scates DK, Venitt S, Spigelman AD, Phillips RKS, Mathers JC, Fodde R. Int J Colorectal Disease 1997; 12: 344-366. 80. Genetic Testing in Australia. Spigelman AD. ANZ J Surg 1998; 68 (Suppl): A50. 81. Disease expression in a large Peutz-Jeghers syndrome family. Scott RJ, Mowat D, Spigelman AD, Phillips MM. J Gastroenterol. Hepatol. 1999; 14 (Suppl.): A66. 82. Relative infrequency of Helicobacter Pylori in the stomach of patients with FAP. Wallace
  21. 21. Professor A.D. Spigelman 21 Curriculum Vitae MH, Forbes A, Spigelman AD, Phillips RKS. J Gastroenterol. Hepatol. 1999; 14 (Suppl.): A68. 83. DNA adduct profiles in the duodenum of patients with FAP given antacids compared to controls. Wallace MH, Forbes A, Spigelman A, Hewer A, Venitt S, Phillips RKS. J Gastroenterol. Hepatol. 1999; 14 (Suppl.): A69. 84. Relaunch of a register for hereditary bowel cancer. French JA, Spigelman AD, Armstrong BA. J Gastroenterol. Hepatol. 1999; 14 (Suppl.): A84. 85. Establishment of a regional family cancer service. Spigelman AD, Turner G, Scott RJ, Meldrum C, Davidson P, Burgess B, Groombridge C, Hammond A. J Gastroenterol. Hepatol. 1999; 14 (Suppl.): A84. 86. In-vitro inhibition of proliferation of a prostate cancer cell line by Indole-3-carbinol, a component of cruciferous vegetables. Spigelman AD, Frydoon far H. Aust NZ J Surg 2000; 70 (Suppl.): A75-76. 87. In-vitro inhibition of proliferation of a colon cancer cell line by Indole-3-carbinol, a component of cruciferous vegetables: mechanism for chemoprevention? Spigelman AD, Frydoon far H. ANZ J Surg 2000; 70 (Suppl.): A64-65. 88. An audit of open and laparoscopic inguinal hernia repair. Spigelman AD, Eno LM. ANZ J Surg 2000; 70 (Suppl.): A80. 89. National Audit of Colorectal Cancer Care Management: - Why & How. Spigelman AD, Anderson S. ANZ J Surg 2000; 70 (Suppl.): A56-57. 90. Patient safety: development of a framework for analysing adverse events. Spigelman AD, Swan JR. ANZ J Surg 2000; 70 (Suppl.): A102-103. 91. Medical record retention – what do clinicians think? Spigelman AD. ANZ J Surg 2000; 70 (Suppl.): A100-101. 92. A Survey of Surgical Audit in Australia. Spigelman AD, Eno LM. ANZ J Surg 2000; 70 (Suppl.): A82. 93. Establishment of a Regional Familial Colorectal Cancer Service. Spigelman AD. ANZ J Surg 2000; 70 (Suppl.): A64. 94. Adverse events in 9 common elective surgical procedures. Kable AK, Gibberd RW, Spigelman AD. ANZ J Surg 2000; 70 (Suppl.): A78. 95. Surgical Adverse Events in Australia. Kable AK, Gibberd RW, Spigelman AD. ANZ J Surg 2000; 70 (Suppl.): A77. 96. Duodenal Cancer in Familial Adenomatous Polyposis. Groves CJ, Saunders BP, Spigelman AD, Phillips RKS. Gut 2001; 48 (Suppl 1): A3. 97. In-vitro inhibition of proliferation of a colon cancer cell line by Sulforaphane, a component of cruciferous vegetables: mechanism for chemoprevention? Frydoon H, Spigelman AD. ANZ J Surg 2001; 71 (Suppl.): A23. 98. The National Colorectal Cancer Care Survey – Progress Report. Anderson SE, Spigelman AD. ANZ J Surg 2001; 71 (Suppl.): A32. 99. Familial Colorectal Cancer: changing the system. Spigelman AD, Scott RJ, Burgess B, Groombridge C, Hammond A. ANZ J Surg 2001; 71: A117. 100.In-vitro inhibition of proliferation of a colon cancer cell line by Indole-3-carbinol, a component of cruciferous vegetables. Frydoon H, Spigelman AD. ANZ J Surg 2001; 71: A118. 101.Development of a Clinical Governance model. Spigelman AD. ANZ J Surg 2002; 72 (Suppl): A1-3. 102.The Management of Colorectal Cancer in Australia. McGrath DR, Spigelman AD, Anderson SE. ANZ J Surg 2002; 72 (Suppl): A19-26. 103.Clinical Governance in Australia. Spigelman AD. Australian Infection Control 2002; 7
  22. 22. Professor A.D. Spigelman 22 Curriculum Vitae (2): Abstracts, 6. 104.The Management of Colorectal Cancer in Australia. McGrath D, Anderson S, Spigelman A. Dis Colon Rectum 2002; 45 (12): A2. 105.Management of Colorectal Cancer in Australia. McGrath DR, Anderson S, Spigelman AD. ANZ J Surg 2003; 73: A5. 106.The Inappropriate Usage of Adjuvant Therapy for Patients with Colorectal Cancer. DR McGrath and AD Spigelman. ANZ J Surg 2003; 73: (Suppl.) A20. 107.Surgeon Volume Impacts on Management of Patients with Colorectal Cancer. DR McGrath and AD Spigelman. ANZ J Surg 2003; 73: (Suppl.) A21. 108.Appropriateness of Surgery for Patients with Symptomatic Gallstones. DR McGrath, RW Gibberd and AD Spigelman. ANZ J Surg 2003; 73: (Suppl.) A38. 109.What Happens to Patients after Discharge? AD Spigelman, R Gibberd and A Kable. ANZ J Surg 2003; 73: (Suppl.) A42. 110.A Review of the Australian Incident Monitoring System. AD Spigelman and JR Swan. ANZ J Surg 2003; 73: (Suppl.) A73. 111.A Method for Measuring Surgical Audit and Peer Review. AD Spigelman and JR Swan. ANZ J Surg 2003; 73: (Suppl.) A74. 112.Skin Antiseptics and Operating Theatre Fires. AD Spigelman and JR Swan. ANZ J Surg 2003; 73: (Suppl.) A75. 113.A Comparison of Concordance with NHMRC Guidelines for Patients treated with Colorectal Cancer in Capital Cities and Elsewhere. DR McGrath and AD Spigelman. ANZ J Surg 2003; 73: (Suppl.) A97. 114.Attenuated Familial Adenomatous Polyposis (AFAP). Lyster Knudsen A, Tomlinson I, AFAP Study Group: Aretz S, et al, Spigelman A. Familial Cancer 2003; 2 (Suppl. 1): 46. 115.Factors influencing the dissemination of genetic information in families with an inherited predisposition to colorectal cancer. Groombridge C, Ingrey A, Gleeson M, Spigelman A, Dudding T. Familial Cancer 2003; 2 (Suppl. 1): 69. 116.Advanced duodenal polyposis: Literature Review and experience with pancreas-sparing duodenectomy in patients with Familial Adenomatous Polyposis. Spigelman AD, Gani J, Burgess B, Groombridge C, Dudding T, Ingrey A, Gleeson M, Scott RJ. Familial Cancer 2003; 2 (Suppl. 1): 84. 117.Appropriateness of surgery for patients with symptomatic gallstones. McGrath DR, Gibberd RW, Spigelman AD. Journal of Gastroenterology and Hepatology 2003; 18 (Suppl.) B2. 118.The inappropriate use of adjuvant therapy for patients with colorectal cancer. McGrath DR, Spigelman AD. Journal of Gastroenterology and Hepatology 2003; 18 (Suppl.) B41. 119.The inappropriate use of adjuvant therapy for patients with colorectal cancer in Australia. McGrath DR, Spigelman AD. EJSO 2003; 29(9): 789. 120.Surgeon Volume Impacts on Management of Patients with Colorectal Cancer in Australia. DR McGrath and AD Spigelman. EJSO 2003: 29(9): 789. 121.Experience with a policy for the introduction of new interventional procedures. AD Spigelman. ANZ J Surg 2004; 74: (Suppl.) A83. 122.The impact of age on the treatment of colorectal cancer in Australia. McGrath DR, Spigelman AD. Ann R Coll Surg Engl 2004; 86: 228. 123.The role of the MLH1 germline epimutation in the development of colorectal cancer. Hitchins M et al, Spigelman A, et al Ward R. Familial Cancer 2005; 4 (Suppl. 1): 43. 124.Informing at-risk relatives in New South Wales families with hereditary bowel cancer
  23. 23. Professor A.D. Spigelman 23 Curriculum Vitae syndromes: evaluation. Groombridge C, Burgess B, Sitas F, Spigelman A, Weir L. Familial Cancer 2005; 4 (Suppl. 1): 47 – 48. 125.Prevalence of germline mutations, Y165C and G382D of the MYH gene in patients with colorectal adenomatous polyps. Scott RJ, Kairupan C, Meldrum CJ, Ashton K, Milward L, Spigelman AD, Kirk J, Tucker K, Ward R. Familial Cancer 2005; 4 (Suppl. 1): 125 - 126. 126.CAPP2: a trial of aspirin and/or resistant starch in people at risk of hereditary non- polyposis colorectal cancer (HNPCC). Macrae FA, Ives PC, Winship I, Boussioutas A, Legget BA, Scott RJ, Spigelman A, Walpole I, Goldblatt J, Burn J. Hereditary Cancer in Clinical Practice 2005; 3(4) (Suppl. 1): S18. 127.Results of an intervention to improve compliance with prophylactic antibiotic protocols for elective surgery. Spigelman AD, Kable AK, Gibberd RW. ANZ J Surg 2006; (Suppl. 1): A28. 128.Preventing litigation: the role of clinical governance. Spigelman AD. ANZ J Surg 2006: (Suppl. 1): A42. MEETING REPORTS 1. Report of the 4th Biennial Meeting of the Leeds Castle Polyposis Group. Spigelman AD. European J Cancer Prev 1991;1: 75-76. 2. FAP Registry Updates – England. Spigelman AD. Hereditary Colon Cancer Newsletter 1991; (2): 5. 3. Report of the 7th Biennial Meeting of the Leeds Castle Polyposis Group. Spigelman AD. Int J Colorectal Disease 1997; 12: 344-366. PRESENTATIONS TO LEARNED SOCIETIES Oral Presentations: 1. Post-cholecystectomy abdominal pain. Spigelman AD, Thomson JPS, Phillips RKS. Royal Society of Medicine (Clinical Section), London, December 9, 1988 (awarded the Alan Edwards Memorial Prize). 2. Gastro-duodenal adenomas in polyposis – is bile the missing link? Spigelman AD, Williams CB, Granowska M, Phillips RKS. British Society of Gastroenterology, Spring Meeting, Bradford, April 13, 1989. 3. Peutz-Jeghers polyps: laissez-faire? Spigelman AD, Williams CB, Phillips RKS. Royal Society of Medicine (Clinical Section), London, April 14, 1989. 4. Desmoid Tumours and viruses. Spigelman AD, Argent S, Wells C, Crofton-Sleigh C, Venitt S, Phillips RKS. Leeds Castle Polyposis Group (Third Biennial Meeting), Dormy House, Worcestershire, June 15-17, 1989. 5. Gastro-duodenal adenomas in polyposis – the role of bile. Spigelman AD, Williams CB, Talbot IC, Granowska M, Phillips RKS. Leeds Castle Polyposis Group (Third Biennial Meeting), Dormy House, Worcestershire, June 15-17, 1989. 6. Upper gastrointestinal polyps in familial adenomatous polyposis. Spigelman AD, Williams CB, Bussey HJR, Phillips RKS. Royal Society of Medicine, Tripartite Meeting (Section of Coloproctology and Colorectal Societies of Australasia and of America), Birmingham, June 19-21, 1989. 7. Relationship between rectal and duodenal polyposis in familial adenomatous polyposis. Spigelman AD, Williams CB, Phillips RKS. Surgical Research Society (72nd meeting), Southampton, July 6, 1990. 8. Detection of DNA adducts in the upper gastrointestinal tract of patients with familial adenomatous polyposis using 32P-postlabelling. Spigelman AD, Phillips RKS, Scates DK, Venitt S. European Environmental Mutagenesis Society,York, UK, July 24, 1990 (Annual Meeting).
  24. 24. Professor A.D. Spigelman 24 Curriculum Vitae 9. DNA adducts in the foregut of patients with familial adenomatous polyposis. Spigelman AD, Phillips RKS, Scates DK, Venitt S. World Sydney, Australia, August 26-30, 1990. 10. Bile reflux and gastric adenomas in patients with familial adenomatous polyposis. Spigelman AD, Granowska M, Phillips RKS. World Congresses of Gastroenterology, Digestive Endoscopy and Colo-Proctology, Sydney, Australia, August 26-30, 1990. 11. Bile reflux and gastric adenomas in patients with familial adenomatous polyposis. Spigelman AD, Granowska M, Phillips RKS. British Society of Gastroenterology, Autumn Meeting, University of Southampton, September 26-28, 1990. 12. Pathogenesis of foregut tumours in familial adenomatous polyposis. Spigelman AD, Scates DK, Venitt S, Phillips RKS. Royal Society of Medicine (Section of Coloproctology), London, November 28, 1990. 13. Significant excess of DNA-adducts in the foregut of patients with familial adenomatous polyposis. Spigelman AD, Scates DK, Venitt S, Phillips RKS. Surgical Research Society (73rd meeting), London, January 1991. 14. Bile and familial adenomatous polyposis: an update. Spigelman AD, Williams CB, Venitt S, Crofton-Sleigh C, Scates DK, Owen RW, Hill MJ, Granowska M, Talbot IC, Farmer CK, Phillips RKS. Leeds Castle Polyposis Group (Fourth Biennial Meeting), Fort Lauderdale, Florida, USA, May 9-11, 1991. 15. Carcinogens in bile: results of a bioassay. Spigelman AD, Scates DK, Venitt S, Phillips RKS. Surgical Research Society (75th meeting), London, January 1992. 16. Carcinogen metabolism and DNA adducts in patients at high risk for intestinal cancer and in controls. Spigelman AD, Venitt S, Scates DK, Nugent KP, Penna C, Foulds S, Bennett PN, Phillips RKS. International Society for Preventive Oncology, Meeting on Cofactor Interactions and Cancer Prevention, Nice, March 17-19, 1993. 17. Sulindac and intestinal polyps: a randomised controlled trial. Spigelman AD, Nugent KP, Farmer KCR, Williams CB, Phillips RKS. International Society for Preventive Oncology, Meeting on Cofactor Interactions and Cancer Prevention, Nice, March 17-19, 1993. 18. Duodenal polyp follow up in FAP. Spigelman AD, Nugent KP, Williams CB, Phillips RKS. Leeds Castle Polyposis Group (Fifth Biennial Meeting), Copenhagen, June 3-5, 1993. 19. The role of duodenotomy in the treatment of duodenal polyposis. Spigelman AD, Penna C, Nugent KP, Tiret E, Phillips RKS. Leeds Castle Polyposis Group (Fifth Biennial Meeting), Copenhagen, June 3-5, 1993. 20. Assessment of hepatic metabolism of carcinogens in FAP and control patients. Spigelman AD, Nugent KP, Bennett PN, Penna C, Foulds S, Phillips RKS. Leeds Castle Polyposis Group (Fifth Biennial Meeting), Copenhagen, June 3-5, 1993. 21. Intestinal cancer and carcinogen exposure. Spigelman AD. St. Mark’s Association (27th Annual Meeting), London, June 25, 1993. 22. Photodynamic therapy for polyps in familial polyposis – first report. Leeds Castle Polyposis Group (Sixth Biennial Meeting), Toronto, May 25-27, 1995. 23. How to harness a hospital IT system to enhance continuity of patient care: a pilot study. Surgical Audit: where are we now? Royal College of Surgeons of England & the Clinical Audit Association. London, January 25, 1996. 24. The Relationship between APC Genotype, Polyp Distribution and Oral Sulindac Treatment in the Colon and Rectum of Patients with Familial Adenomatous Polyposis (FAP). Scott RJ, Guldenschuh I, Hurlimann R, Muller A, Ammann R, Mullhaupt B, Dobbie Z, Zala GF, Flury R, Seelentag W, Roth J, Meyenberger C, Fried M, Hoppeler T and Spigelman AD. Genetics into the New Millenium. 23rd Annual Scientific Meeting of the Human Genetics Society of Australasia and 13th Annual Scientific Meeting of the
  25. 25. Professor A.D. Spigelman 25 Curriculum Vitae Australasian Society for Inborn Errors of Metabolism. 30 August – 2 September 1999, EventSite, Australian Technology Park, Sydney, Australia. 25. In-vitro inhibition of proliferation of a prostate cancer cell line by Indole-3-carbinol, a component of cruciferous vegetables. Annual Scientific Congress, Royal Australasian College of Surgeons, Melbourne, May 7-12, 2000. 26. An audit of open and laparoscopic inguinal hernia repair. Annual Scientific Congress, Royal Australasian College of Surgeons, Melbourne, May 7-12, 2000. 27. National audit of colorectal cancer care management: - Why & How. Annual Scientific Congress, Royal Australasian College of Surgeons, Melbourne, May 7-12, 2000. 28. Patient safety: development of a framework for analysing adverse events. Annual Scientific Congress, Royal Australasian College of Surgeons, Melbourne May 7-12, 2000. 29. Medical record retention – what do clinicians think? Annual Scientific Congress, Royal Australasian College of Surgeons, Melbourne, May 7-12, 2000. 30. Familial Colorectal cancer: Changing the system. Annual Scientific Meeting, Surgical Research Society of Australasia, Adelaide, August 10, 2000. 31. In-vitro inhibition of proliferation of a colon cancer cell line by Indole-3-carbinol, a component of cruciferous vegetables. Frydoon far H, Spigelman AD. Annual Scientific Meeting, Surgical Research Society of Australasia, Adelaide, August 11, 2000. 32. Genetic disrimination experienced by Australian families affected by hereditary bowel cancer. 3rd Joint Meeting, Leeds Castle Polyposis Group and International Collaborative Group for Hereditary Non-Polyposis Colorectal Cancer, Venice, April 26-28, 2001. 33. Familial Colorectal cancer: Improving the System. 3rd Joint Meeting, Leeds Castle Polyposis Group and International Collaborative Group for Hereditary Non-Polyposis Colorectal Cancer, Venice, April 26-28, 2001. 34. In-vitro inhibition of proliferation of a colon cancer cell line by Sulforaphane, a component of cruciferous vegetables. Annual Scientific Congress, Royal Australasian College of Surgeons, Canberra, May 6-11, 2001. 35. Implementing Clinical Governance. Opening Plenary Session, Annual Scientific Congress, Royal Australasian College of Surgeons, Adelaide, May 11, 2002. 36. Clinical Governance in Australia. Australian Infection Control Association Second Biennial Conference, Brisbane, June 7, 2002. 37. The National Colorectal Cancer Care Survey - Results. Clinical Oncological Society of Australia Annual Scientific Meeting. Sydney, November 28. 2002. 38. What happens to Patients after Discharge? Annual Scientific Congress, Royal Australasian College of Surgeons, Brisbane, May 8, 2003. 39. A Review of the Australian Incident Monitoring System. Annual Scientific Congress, Royal Australasian College of Surgeons, Brisbane, May 7, 2003. 40. A Method for Measuring Surgical Audit and Peer Review. Annual Scientific Congress, Royal Australasian College of Surgeons, Brisbane, May 7, 2003. 41. Skin Antiseptics and Operating Theatre Fires. Annual Scientific Congress, Royal Australasian College of Surgeons, Brisbane, May 8, 2003. 42. Measuring Clinical Audit and Peer Review Practice - the Hunter Health Experience. Institute for International Research (IIR) 3rd Annual Adverse Events Conference, Melbourne, July 29, 2003. 43. National Patterns of Care for Colorectal Cancer. Combined Australasian Colorectal Scientific Meeting, Sydney, September 19-20, 2003. 44. Colorectal Cancer Patterns of Care. Hunter Surgical Society Meeting, Nelson Bay, November 2, 2003.
  26. 26. Professor A.D. Spigelman 26 Curriculum Vitae 45. Experience with a policy for the introduction of new interventional procedures. Annual Scientific Congress, Royal Australasian College of Surgeons, Melbourne, May 4, 2004. 46. Preventing litigation: the role of clinical governance. Annual Scientific Congress, Royal Australasian College of Surgeons, Sydney, May 15, 2006. 47. Results of an intervention to improve compliance with prophylactic antibiotic protocols for elective surgery. Annual Scientific Congress, Royal Australasian College of Surgeons, Sydney, May 18, 2006. 48. Clinical Governance; a potpourri of experience from NSW. Institute for International Research (IIR) 6th Annual Adverse Event Management Congress, Melbourne, June 14, 2006. Posters: 1. Cystic pancreatic endocrine tumours. Spigelman AD, Ham JM. First World Congress of Hepato-Pancreatico-Biliary Surgery, Lund, Sweden, June 9-13, 1986. 2. Bile acid profiles in familial adenomatous polyposis. Spigelman AD, Owen RW, Hill MJ, Phillips RKS. Royal Society of Medicine, Tripartite Meeting (Section of Coloproctology and Colorectal Societies of Australia and of America), Birmingham, June 19-21, 1989. 3. Bile mutagenicity and familial adenomatous polyposis. Spigelman AD, Crofton-Sleigh C, Venitt S, Phillips RKS. Royal Society of Medicine, Tripartite Meeting (Section of Coloproctology and Colorectal Societies of Australia and of America), Birmingham, June 19-21, 1989. 4. The malignant potential of Peutz-Jeghers syndrome. Spigelman AD, Murday V, Phillips RKS. Royal Society of Medicine, Tripartite Meeting (Section of Coloproctology and Colorectal Societies of Australia and of America), Birmingham, June 19-21, 1989. 5. Rectal polyposis severity – a guide to duodenal polyposis severity in familial adenomatous polyposis? Spigelman AD, Williams CB, Phillips RKS. World Congresses of Gastroenterology, Digestive Endoscopy and Colo-Proctology, Sydney, Australia, August 26-30, 1990. 6. Carcinogen metabolism and DNA adduct formation in FAP patients and in controls. Spigelman AD, Nugent KP, Scates DK, Penna C, Foulds S, Bennett PN, Venitt S, Phillips RKS. Tripartite Meeting (Section of Coloproctology and Colorectal Societies of Australasia and of America), Sydney, Australia, October 17-20, 1993. 7. The one-stop breast clinic. First European Forum on Quality Improvement in Health Care. London, March 9, 1996. 8. Bile from transgenic mice carrying a mutation in the APC gene induces more DNA damage than does bile from wild-type mice from the same genetic background. Scates DK, Venitt S, Spigelman AD, Phillips RKS, Mathers JC, Fodde R. British Society of Gastroenterology Spring Meeting, Brighton, March 20-22 1996. 9. Foregut screening in familial adenomatous polyposis (FAP). Spigelman AD, Phillips RKS, Williams CB, Bussey HJR. British Society of Gastroenterology, Autumn Meeting, Sheffield, September 14-16, 1988. 10. Upper gastro-intestinal screening in familial adenomatous polyposis (FAP). Spigelman AD, Phillips RKS, Williams CB, Bussey HJR. Association of Surgeons of Great Britain and Ireland, Annual Meeting, Edinburgh, March 29-31, 1989. 11. Gallbladder bile acids in familial adenomatous polyposis. Spigelman AD, Owen RW, Hill MJ, Phillips RKS. Association of Surgeons of Great Britain and Ireland, Annual Meeting, Edinburgh, March 29-31, 1989. 12. Ornithine decarboxylase activity in premalignant conditions of the upper gastro-intestinal tract. Alstead EM, Brito FCG, Spigelman AD, Phillips RKS, Clark ML, Farthing MJG. Medical Research Society of Great Britain, Leeds, June 30, 1989.
  27. 27. Professor A.D. Spigelman 27 Curriculum Vitae 13. Peroperative enteroscopy in Peutz-Jeghers polyposis Phillips RKS, Spigelman AD, Thomson JPS. British Society of Gastroenterology, Autumn Meeting, Dublin, September 27-29, 1989. 14. Detection by 32P-Postlabelling of DNA adducts in the upper gastrointestinal tract of patients with familal adenomatous polyposis. Spigelman AD, Phillips RKS, Scates DK, Venitt S. British Association for Cancer Research (31st Annual Meeting), University of Sussex, March 20-22, 1990. 15. Evaluation of ornithine decarboxylase (ODC) activity as a marker for premalignancy in the stomach and duodenum. Alstead EM, Brito FCG Spigelman AD, Phillips RKS, Clark ML, Farthing MJG. America Gastroenterological Association, San Antonio, Texas, May 12-18, 1990. 16. Excess of DNA-adducts in the foregut of patients with familial adenomatous polyposis. Spigelman AD, Scates DK, Venitt S, Williams CB, Phillips RKS. British Society of Gastroenterology, Autumn Meeting, University of Southampton, September 26-28, 1990. 17. Bile and DNA damage in an animal model. Spigelman AD, Scates DK, Venitt S, Phillips RKS. British Society of Gastroenterology, Autumn Meeting, University of London, September 25-27, 1991. 18. Acetylator status: link between hepatic metabolism and colorectal cancer. Farmer KCR, Oliver SE, Spigelman AD, Bennett PN, Phillips RKS. British Society of Gastroenterology, Autumn Meeting, University of London, September 25-27, 1991. 19. Duodenal polyp progression: a longitudinal study in patients with familial adenomatous polyposis (FAP). Nugent KP, Spigelman AD, Williams CB, Phillips RKS. British Society of Gastroenterology, Spring Meeting, Sheffield, March 1992. 20. Adducts, detected by 32P-postlabelling, in DNA treated in-vitro with bile from patients with familial adenomatous polyposis and from unaffected controls. Scates DK, Spigelman AD, Phillips RKS, Venitt S. Sixth International Conference on Environmental Mutagens (“ICEM”), Melbourne, Australia, February 21-26, 1993. 21. Pouches in patients with familial adenomatous polyposis (FAP) are not at increased risk for neoplasia. Nugent KP, Spigelman AD, Nicholls RJ, Talbot IC, Phillips RKS. Royal Society of Medicine (Section of Coloproctology), London, February 24, 1993. 22. Bile and DNA adducts – an in-vitro genotoxicity study. Spigelman AD, Scates DK, Venitt S, Nugent KP, Phillips RKS. British Society of Gastroenterology, Spring Meeting, University of Manchester, March 1993. 23. Outcome of duodenotomy for duodenal polyposis in patients with familial adenomatous polyposis. Spigelman AD, Penna C, Nugent KP, Phillips RKS. British Society of Gastroenterology, Spring Meeting, University of Manchester, March 1993. 24. GST Mu1 genetic polymorphism in familial adenomatous polyposis (FAP). Debinski HS, Cottrell S, Phillips RKS, Spigelman AD. British Society of Gastroenterology, Annual Meeting, Heriot-Watt University, 21-23 September 1994. 25. DNA ploidy studies of sporadic colorectal polyps. Tahir-Kheli ND, Sarker SK, Levine TS, Spigelman AD, Coleman DV. Pathology Society, 1995. 26. p53 alteration occurs more frequently than ras mutation in duodenal adenomas in familial adenomatous polyposis. Kashiwagi H, Spigelman AD, Debinski HS, Talbot IC, Phillips RKS. Pathology Society, 1995. 27. Colorectal polyp density equates with cancer risk in familial adenomatous polyposis. Debinski H, Neale K, Love S, Phillips R, Spigelman A. The American Society of Colon & Rectal Surgeons, 94th Annual Convention, Montreal, May 7-12, 1995. 28. “Major” ampullary polyposis progresses more rapidly than does “minor” ampullary polyposis. Kashiwagi H, Spigelman AD, Debinski HS, Talbot IC, Phillips RKS. Leeds
  28. 28. Professor A.D. Spigelman 28 Curriculum Vitae Castle Polyposis Group (Sixth Biennial Meeting), Toronto, May 25-27, 1995. 29. Further studies of the role of bile in foregut neoplasia in patients with familial adenomatous polyposis. Venitt S, Scates DK, Philips RKS, Spigelman AD. Leeds Castle Polyposis Group (Sixth Biennial Meeting), Toronto, May 25-27, 1995. 30. Endoscopic ultrasound (EUS) – a new tool for assessment of the foregut in FAP patients. Debinski H, Muller A, Spigelman AD, Hatfield A, Phillips RKS. Leeds Castle Polyposis Group (Sixth Biennial Meeting), Toronto, May 25-27, 1995. 31. Can we now safely delay prophylactic colectomy in FAP? Spigelman AD, Debinski HS, Neale K, Phillips RKS. Leeds Castle Polyposis Group (Sixth Biennial Meeting), Toronto, May 25-27, 1995. 32. Familial adenomatous polyposis: the risk of extracolonic cancer. Nugent KP. Spigelman AD, Phillips RKS. Leeds Castle Polyposis Group (Sixth Biennial Meeting), Toronto, May 25-27, 1995. 33. A prospective double-blind placebo controlled study of the management of duodenal and rectal polyps in familial adenomatous polyposis with low dose aspirin, using several measures of outcome. Debinski HS, Desai D, Spigelman AD, Phillips RKS. Leeds Castle Polyposis Group (Sixth Biennial Meeting), Toronto, May 25-27, 1995. 34. Regression of small duodenal polyps after sulindac treatment in patients with FAP. Trojan J, Debinsky HS, Spigelman AD, Williams CB, Phillips RKS. 4th United European Gastroenterology Week, Berlin, September 17-21, 1995. 35. How we improved our day care rates. Spigelman AD, Alexander S, Hittinger R. 2nd International Congress on Ambulatory Surgery, London, 15-18 April, 1997. 36. Studies of the nature and origin of DNA adducts formed by bile from patients with familial adenomatous polyposis and from normal patients. Venitt S, Scates DK, Spigelman AD, Phillips RKS. Leeds Castle Polyposis Group (Seventh Biennial Meeting), The Netherlands, June 6-7, 1997. 37. Relaunch of a Register for Hereditary Bowel Cancer. French JA, Spigelman AD, Armstrong BA. 2nd Joint Meeting, Leeds Castle Polyposis Group and International Collaborative Group for Hereditary Non-Polyposis Colorectal Cancer, Melbourne and Lorne, Australia. 1 – 6 March 1999. 38. Establishment of a Regional Family Cancer Service. Spigelman AD, Turner G, Scott RJ, Meldrum C, Davidson P, Burgess B, Groombridge C and Hammond A. 2nd Joint Meeting, Leeds Castle Polyposis Group and International Collaborative Group for Hereditary Non-Polyposis Colorectal Cancer, Melbourne and Lorne, Australia. 1 – 6 March 1999. 39. APC Gene Testing in patients with Multiple Adenomas of the Colon. Scott RJ, Meldrum C, Crooks R, Groombridge C, Turner G, Spigelman AD, Kirk J, Tucker K and Scott RJ. Genetics into the New Millenium. 23rd Annual Scientific Meeting of the Human Genetics Society of Australasia and 13th Annual Scientific Meeting of the Australasian Society for Inborn Errors of Metabolism. 30 August – 2 September 1999, EventSite, Australian Technology Park, Sydney. 40. Disease Expression in a Large Peutz-Jeghers Syndrome Family. Scott RJ, Mowat D, Spigelman AD, McPhillips M. Genetics into the New Millenium. 23rd Annual Scientific Meeting of the Human Genetics Society of Australasia and 13th Annual Scientific Meeting of the Australasian Society for Inborn Errors of Metabolism. EventSite, Australian Technology Park, Sydney, 30 August – 2 September 1999. 41. In-vitro inhibition of proliferation of a prostate cancer cell line by Indole-3-carbinol, a component of cruciferous vegetables. Urological Society of Australia & Genito-Urinary Oncology Symposium, Sydney, March 23 – 24, 2000.
  29. 29. Professor A.D. Spigelman 29 Curriculum Vitae 42. A Survey of Surgical Audit in Australia. Annual Scientific Congress, Royal Australasian College of Surgeons, Melbourne, May 7-12, 2000. 43. Establishment of a Regional Familial Colorectal Cancer Service. Annual Scientific Congress, Royal Australasian College of Surgeons, Melbourne, May 7-12, 2000. 44. In-vitro inhibition of proliferation of a colon cancer cell line by Indole-3-carbinol, a component of cruciferous vegetables: mechanism for chemoprevention? Annual Scientific Congress, Royal Australasian College of Surgeons, Melbourne, May 7-12, 2000. 45. In-vitro study of a GST-mu stimulating agent on a colorectal cancer cell line. 3rd Joint Meeting, Leeds Castle Polyposis Group and International Collaborative Group for Hereditary Non-Polyposis Colorectal Cancer, Venice, April 26-28, 2001. 46. Genetic heterogeneity and disease diversity in FAP. 3rd Joint Meeting, Leeds Castle Polyposis Group and International Collaborative Group for Hereditary Non-Polyposis Colorectal Cancer, Venice, April 26-28, 2001. 47. Phenotypic characteristics of HNPCC families sub-divided according to their mutation status. 3rd Joint Meeting, Leeds Castle Polyposis Group and International Collaborative Group for Hereditary Non-Polyposis Colorectal Cancer, Venice, April 26-28, 2001. 48. The NSW & ACT Hereditary Bowel Cancer Registers: a progress report. 3rd Joint Meeting, Leeds Castle Polyposis Group and International Collaborative Group for Hereditary Non-Polyposis Colorectal Cancer, Venice, April 26-28, 2001. 49. The National Colorectal Cancer Care Survey: Progress Report. Annual Scientific Congress, Royal Australasian College of Surgeons, Canberra, May 6-11, 2000. 50. Cordinating a statewide system for informing at-risk relatives in NSW families with hereditary bowel cancer syndromes. 5th Australian Conference on Familial and Genetic Aspects of Cancer, Barossa Valley, South Australia, July 4-6, 2002. 51. The Management of Colorectal Cancer in Australia. Tripartite Colorectal Surgery Meeting, RSM Section of Coloproctology, Colorectal Surgical Society of Great Britain and Colorectal Societies of Australia and of America Melbourne, October 27-30, 2002. 52. The post-discharge complication rate in surgical patients and their subsequent management. 19th Conference of International Society for Quality in Healthcare, Paris, November 5-8, 2002. 53. The Inappropriate Usage of Adjuvant Therapy for Patients with Colorectal Cancer. Annual Scientific Congress, Royal Australasian College of Surgeons, Brisbane, May 7, 2003. 54. Surgeon Volume Impacts on Management of Patients with Colorectal Cancer. Annual Scientific Congress, Royal Australasian College of Surgeons, Brisbane, May 7, 2003. 55. Results of an intervention to improve compliance with prophylactic antibiotic protocols for Elective Surgery. National Australian Conference on Safety and Quality in Health Care, Perth, Western Australia, July 14-16, 2003. 56. The variable effect on proliferation of a colon cancer cell line by the citrus fruit flavonoid Naringenin. Annual Scientific Meeting, Surgical Research Society, Melbourne, August 29 – 30, 2003. 57. Appropriateness of surgery for patients with symptomatic gallstones. DR McGrath, RW Gibberd and AD Spigelman. Australian Gastroenterology Week, Cairns, October 7-10, 2003. 58. The inappropriate usage of adjuvant therapy for patients with colorectal cancer. McGrath DR, Spigelman AD. UK Association of Surgeons in Training, Sheffield, February 20-22, 2004. 59. Surgeon volume impacts on management of patients with colorectal cancer. McGrath
  30. 30. Professor A.D. Spigelman 30 Curriculum Vitae DR, Spigelman AD. UK Association of Surgeons in Training, Sheffield, February 20-22, 2004. 60. A multifaceted computer-based intervention to improve cessation care in a surgical preadmission clinic. Wolfenden L, Knight J, Campbell E, Spigelman AD, Kerridge R, Moore K. 18th World Conference on Health Promotion & Health Education, Melbourne, April 26-28, 2004. 61. Evaluation of the system for informing at-risk relatives in NSW families with hereditary bowel cancer syndromes. Spigelman AD, Weir L, Burgess B, Groombridge C, Overkov A. Familial Cancer 2004: Research and Practice, Couran Cove Island Resort, Queensland, August 2004. INVITED LECTURES / TALKS 1988 • Upper gastrointestinal neoplasia in familial adenomatous polyposis. St. Mark’s Hospital, London, April 6, 1988 • What’s new in polyposis? Department of Gastroenterology, St. Bartholomew’s Hospital, London, April 15, 1988 • Peutz-Jeghers syndrome: benign or malignant? St. Mark’s Hospital, London, July 1, 1988. • Upper gastrointestinal disease in familial adenomatous polyposis: research at St. Mark’s Hospital, London. Gastroenterology Unit, Prince of Wales Hospital, Sydney, July 12, 1988. • Polyps and Polyposis syndromes. St. Mark’s Postgraduate Lecture Course, London, October 14, 1988 & March 3, 1989 • Polyposis as a model for colorectal cancer – update on clinical and experimental studies. St. Mark’s Hospital, London, October 28, 1988 • Unusual aspects of familial adenomatous polyposis. Kings College Hospital, London, November 23, 1988 1989 • Foregut screening in familial adenomatous polyposis: findings and implications. Gastroenterology Unit, Whittington Hospital, London, February 23, 1989 • Foregut disease in polyposis coli – a contradiction in terms. Department of Gastroenterology and Nutrition, Central Middlesex Hospital, London, October 13, 1989 • Duodenal polyposis and desmoid tumours. St. Mark’s Hospital Postgraduate Course, London, October 13, 1989 1990 • Bile and polyps in familial adenomatous polyposis. Combined Gastroenterology meeting, Royal Prince Alfred Hospital, Sydney, February 21, 1990 • The foregut in familial adenomatous polyposis. Combined Gastroenterology meeting, Concord Repatriation Hospital, Sydney, February 26, 1990 • Polyposis of the foregut. St. Mark’s Postgraduate Teaching Programme, May 23, 1990; January 30 1991; May 22 1991 • Colorectal cancer, polyposis and bile. Surgical Meeting, Central Middlesex Hospital, London, June 1, 1990 • Bile, colorectal cancer and polyposis. Surgical Meeting, St. Mary’s Hospital, London, June 11, 1990 • Colorectal cancer risk and uretero-sigmoidostomy. CombinedGastroenterology meeting, St. Mary’s Hospital, London, June 15, 1990

×